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Resumo 
Nos últimos anos, tem-se observado um aumento na produção de novas drogas 
que, por serem substâncias novas no mercado, são vendidas e consideradas como 
“drogas legais”. Por esta razão, os consumidores, erradamente, consideram-nas 
seguras para consumo. No entanto, têm sido recentemente reportados vários casos de 
intoxicações e mortes por drogas legais. Um exemplo destas drogas é a 3-
metilmetcatinona (3-MMC ou metafedrona). Esta droga, que pertence à família das 
catinonas sintéticas, foi introduzida no mercado com o objetivo de substituir a 4-
metilmetcatinona (4-MMC ou mefedrona), que já é considerada uma droga ilegal. Com 
o aumento do consumo da 3-MMC, a avaliação da sua toxicidade tornou-se 
imprescindível. A maioria dos dados sobre os efeitos deletérios da 3-MMC provêm dos 
poucos relatos de casos clínicos, mas é necessária uma pesquisa mais aprofundada 
sobre as suas propriedades farmacológicas e toxicológicas para avaliar o potencial 
nocivo da droga. De facto, devido à escassez de informação sobre a droga: é de 
grande importância verificar os efeitos tóxicos em diversos órgãos-alvo, uma vez que 
não existem dados consistentes publicados, bem como descobrir as vias metabólicas, 
e a relevância do metabolismo da 3-MMC nos seus efeitos toxicológicos. Por estes 
motivos, os nossos objetivos foram: (i) estudar os mecanismos subjacentes à sua 
toxicidade e (ii) caracterizar o perfil metabólico da 3-MMC, investigando a possível 
relação entre ambos. 
Como o fígado é um dos principais locais do metabolismo das drogas e, por isso, 
um alvo relevante para os seus efeitos deletérios, escolhemos os hepatócitos 
primários de rato como modelo para estudos in-vitro. Para este fim, foram isolados 
hepatócitos primários de ratos Wistar pelo método de perfusão com colagenase. Estes 
foram semeados e expostos durante 24h a várias concentrações da 3-MMC (31 nM – 
10 mM), de forma a obter um perfil citotóxico completo. A morte celular foi avaliada por 
três métodos: (i) pelo ensaio de redução do brometo de 3-(4,5-dimetil-tiazol-2-il)-2,5-
difeniltetrazólio (MTT); (ii) pelo ensaio da incorporação do corante vermelho neutro 
(NR); e (iii) pelo ensaio de libertação de lactato desidrogenase (LDH). Depois de expor 
as células às concentrações de 1 µM, 10 µM, 100 µM, e 500 µM de 3-MMC durante 24 
h, foram avaliados alguns mecanismos de ação responsáveis pela citotoxicidade. 
Nomeadamente, através da medição da produção de espécies reativas de oxigénio e 
azoto (ROS/RNS), de glutationa reduzida (redGSH) e oxidada (GSSG), de trifosfato de 
adenosina (ATP), alterações ao potencial de membrana da mitocôndria (ΔΨm) e a 
atividade das caspases-3, -8, -9. Finalmente, avaliámos os efeitos dos inibidores do 
citocromo P450 (CYP) na toxicidade da 3-MMC. Relativamente aos ensaios de 
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viabilidade, observou-se toxicidade a concentrações mais baixas no lisossoma (NR 
NOEC 312.5 µM), do que aquelas necessárias para causar dano na mitocôndria (MTT 
NOEC 379.5 µM) e na membrana citoplasmática (LDH NOEC 1.04 mM). De uma 
maneira geral, observámos um decréscimo dependente da concentração nas defesas 
antioxidantes (redGSH) paralelo com um aumento de GSSG. Verificou-se uma 
tendência, dependente da concentração, para o aumento da produção de ROS/RNS 
que se tornou particularmente significativo a partir da concentração de 10 µM. Nesta 
concentração, as atividades das caspases-3, -8 e -9 foram significativamente 
elevadas, mas não se observaram diferenças nas concentrações mais altas, indicando 
que nessas concentrações devem intervir outros mecanismos. Não foram observadas 
alterações significativas no potencial de membrana da mitocôndria (ΔΨm), que é 
importante para a síntese de ATP e, por isso, para a apoptose. Em concordância com 
estes resultados, a 3-MMC apenas interferiu significativamente com o estado 
energético da célula em concentrações superiores a 10 µM. Os nossos resultados 
também demonstraram que a inibição da CYP2D6 diminuiu a toxicidade da 3-MMC, 
enquanto que a inibição da CYP2E1 exacerbou os efeitos deletérios da 3-MMC (este 
efeito foi apenas observado para concentrações superiores a 1.20 mM). 
A caracterização do perfil metabólico foi realizada para os hepatócitos primários 
de rato através da adaptação de um método de cromatografia gasosa acoplada a um 
detetor de massa (GC-MS) para identificação e quantificação dos analitos. O método 
otimizado mostrou alta sensibilidade e desempenho adequado para a identificação e 
quantificação da 3-MMC. Em testes preliminares, o método apresenta linearidade, 
limites de deteção e quantificação, ausência de interferências e uma recuperação da 
extração aceitável para a análise das amostras selecionadas. Os resultados deste 
estudo são bastante preliminares, uma vez que apenas pudemos identificar e 
quantificar o composto-pai nas amostras analisadas; a identificação e a quantificação 
dos metabolitos da 3-MMC não foram realizadas. De uma forma geral, a baixas 
concentrações, a inibição da CYP2E1, da CYP2D6 e a inibição geral do CYP450, 
diminuíram a extensão metabólica. Uma hipótese plausível é que as vias alternativas 
que biotransformam a droga quando estas enzimas não estão disponíveis, possam 
sofrer o fenómeno de saturação. Apesar de preliminar, a nossa metodologia 
demonstrou resultados promissores, no entanto, é essencial a validação do método e 
a análise de um número maior de amostras. 
Em geral, os resultados envolvem o metabolismo e o stress oxidativo na 
hepatotoxicidade da 3-MMC, que parece ser desencadeada tanto por mecanismos 
apoptóticos intrínsecos quanto extrínsecos. Em concentrações mais elevadas de 3-
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MMC, podem estar a intervir outras vias de morte celular, como por exemplo, a 
necrose ou a autofagia, necessitando de mais investigação. 
 
Palavras-chave: 3-metilmetcatinona (3-MMC) – Novas substâncias psicoativas 
(NPS) – Catinonas sintéticas – Toxicidade – Stress oxidativo – Metabolismo – 
Apoptose  
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Abstract 
Recently, there has been an increase in the production of new psychoactive 
substances (NPS). Due to the novelty of these drugs, they are usually not under legal 
control, and are therefore considered licit drugs. For this reason, users mistakenly 
consider them as safe for consumption. However, there are several reports of cases of 
intoxications and deaths by NPS. An example of such a drug is 3-methylmethcathinone 
(3-MMC or metaphedrone). This drug, which belongs to the synthetic cathinones 
family, was introduced recently in the market to replace 4-methylmethcathinone (4-
MMC) that was made illegal. With the increase in consumption of 3-MMC, its toxicity 
assessment has become mandatory. Most data on the deleterious effects of 3-MMC 
come from few case reports of intoxications, but further investigation on its toxicological 
properties is therefore required to evaluate the harmful potential of the drug. Indeed, by 
virtue of the scarce available information on the drug: it is of great importance to clearly 
ascertain the toxic effects on diverse target organs, as consistent data published on the 
subject is absent, as well as to reveal metabolic pathways and their relevance for the 
toxicological effects of 3-MMC. In addition, it is also highly relevant to study 
pharmacokinetics in different animal models and to scrutinize the signalling pathways 
triggering the known detrimental toxicological effects. For these reasons, our goals 
were: (i) to study the mechanisms underlying the toxicity of 3-MMC and (ii) to 
characterize the metabolic profile of 3-MMC, investigating a potential relationship 
between metabolism and toxicity.  
As the liver is one of the main sites of drug metabolism, and therefore a relevant 
target for their deleterious effects, we chose the primary rat hepatocytes as an in-vitro 
model. For this purpose, primary hepatocytes of Wistar rats were isolated by a two-step 
collagenase perfusion, cultured, and exposed for 24 h to several concentrations of the 
drug (31 nM to 10 mM), selected to provide a complete cytotoxic profile. Cell death was 
assessed through three assays: (i) the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) reduction assay (ii) the neutral red (NR) uptake 
assay and (iii) lactate dehydrogenase (LDH) leakage assay. Afterwards, some of the 
mechanisms that contributed to the putative cytotoxicity were also assessed by 
measuring the intracellular reactive species of oxygen and nitrogen (ROS/RNS), 
reduced (GSH) and oxidized (GSSG) glutathione, adenosine triphosphate (ATP), 
alterations to the mitochondrial membrane potential (ΔΨm), and to caspase-3, -8 and -
9 activities, after exposing cells at 1 μM, 10 μM, 100 μM, and 500 µM of 3-MMC for 24 
h. Finally, we evaluated the modulatory effects of cytochrome P450 (CYP) inhibitors on 
the toxicity of 3-MMC. 3-MMC-induced toxicity was perceived in the lysosome at lower 
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concentrations (NR NOEC 312.5 µM) than those needed to cause damage to 
mitochondria (MTT NOEC 379.5 µM) and cytoplasmic membrane (LDH NOEC 1.04 
mM). Overall, we observed a concentration-dependent shortage in antioxidant 
defences (redGSH) with a concurrent increase of GSSG. A significant concentration-
dependent increase of ROS/RNS was at concentrations higher than 10 μM. At this 
concentration, caspase-3, -8, and -9 activities were significantly elevated, but no 
differences were observed at higher concentrations, indicating that at these 
concentration levels other mechanisms should intervene. No significant alterations 
were observed in the ΔΨm, which is important for ATP synthesis, and therefore for 
energy-dependent apoptosis. In line with these finding, 3-MMC only significantly 
interfered with the cell energetic status at concentrations higher than 10 μM. Our data 
also demonstrated that CYP2D6 inhibition diminished 3-MMC toxicity, while on the 
contrary CYP2E1 inhibition exacerbated the deleterious effects of 3-MMC (but this 
effect was only observed at concentrations higher than 1.20 mM). 
The characterization of the metabolic profile was performed for the primary rat 
hepatocytes by adapting a gas chromatography-mass spectrometry (GC-MS) method 
for identification and quantification of compounds. The optimized method showed high 
sensitivity and adequate performance for the identification and quantification of 3-MMC. 
In the preliminary tests, the method showed linearity, detection and quantitation limits, 
lack of interferences and acceptable extraction efficiency for the analysis of selected 
samples he results in this study are very preliminary because we could only identify 
and quantify the parent drug in the samples tested; identification and quantification of 
3-MMC metabolites was not performed. Overall, at low concentration levels, inhibition 
of CYP2E1, CYP2D6 and general inhibition of CYP450, increased metabolic extent. 
For high concentrations, the metabolism diminished, when CYP2E1 and CYP3A4 were 
inhibited. We hypothesised that alternative metabolic pathways that biotransform the 
drug when these enzymes are not available could suffer saturation. Although 
preliminary, our methodology showed promising results, but it is essential to validate 
the method and to increase the number of samples analysed. 
Overall, our data implicates the metabolism and the oxidative burst in the 
hepatotoxicity of 3-MMC, which seems to be triggered both by intrinsic and extrinsic 
apoptotic mechanisms. At higher drug concentrations, other cell death pathways might 
be at play, such as necrosis, deserving further investigation. 
 
Keywords: 3-methylmethcathinone (3-MMC) – New psychoactive substance 
(NPS) – Synthetic cathinones – Toxicity – Oxidative stress – Metabolism – Apoptosis 
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Thesis layout 
This thesis is divided into 6 chapters. The first chapter is a general introduction 
that comprises the current state of the art on 3-methylmethcathinone (3-MMC). The 
second chapter encompasses the main objectives of this thesis. The third chapter 
consists of the description of the experimental work and methodologies used in the 
realization of the work conducted in the ambit of this thesis. The forth chapter 
comprises the results obtained and the respective discussion. The fifth chapter 
contains the main conclusions from the conducted work, as well as potential future 
studies. The sixth chapter contains the bibliography cited. 
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General Introduction 
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1.1. Introduction 
Cathinone is a natural psychoactive component found in the leaves of the Catha 
edulis plant, known as khat (Valente et al. 2014). Khat grows wild in the Horn of Africa 
and in the Southwest of the Arabian Peninsula and is usually consumed by chewing 
the fresh leaves, in sessions where men gather together and consume it (Valente et al. 
2014). As the routes for transportation and distribution improved, the availability and 
use of khat leaves spread to Western countries (Griffiths et al. 2010; Valente et al. 
2014). Cathinone is referred to as a natural amphetamine (1-phenylpropan-2-amine) 
due to their close chemical structure (it corresponds to the -keto analogue of 
amphetamine) and similar effects (Carvalho et al. 2012). 
The first synthetic cathinones were synthetized in the late 1920’s for medical 
purposes and began being sold as recreational drugs in the 2000’s (Brandt et al. 2011; 
Coppola and Mondola 2012). Methcathinone (ephedrone) and 4-methylmethcathinone 
(4-MMC or mephedrone) were the first synthetic cathinones produced (Valente et al. 
2014). These drugs are often sold as “bath salts” or “plant food” (Valente et al. 2014) 
and labelled “not for human consumption” or “research chemical” to circumvent drug 
abuse laws (Dargan et al. 2011). These and other frequently abused synthetic 
cathinones are shown in Table 1. 
4-MMC is one of the most popular synthetic cathinones and its abuse was first 
detected in 2007 (EMCDDA 2010b). Users of 4-MMC describe its effects as similar to 
those of 3,4-methylenedioxymethamphetamine (MDMA) but with stronger feelings of 
craving (Zawilska 2014). The most frequently used routes of administration are 
insufflation (snorted) and oral (referred to as “bombing”, i.e. the ingestion of capsules or 
powder wrapped in cigarette paper) (Zawilska 2014). As its consumption increased, 
toxicity reports also peaked and as a result, several countries banned 4-MMC. As a 
consequence, the market quickly evolved for a new generation of synthetic cathinones, 
with the appearance of new structurally-related derivatives (Shimshoni et al. 2015). In 
this context, 3-methylmethcathinone (3-MMC) first appeared in Sweden in 2012 as a 
“legal drug” to substitute for 4-MMC (Backberg et al. 2015), and was mostly sold on the 
internet as a research chemical. Like other synthetic cathinones, 3-MMC has no known 
therapeutic use (WHO 2016). 
This novel designer drug is usually found in the form of white powder or crystals. 
Users describe its effects as similar to, but less potent and intense than those of 
MDMA and mephedrone (Adamowicz et al. 2016a). Repeated administration in a single 
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session is a common consequence of the short duration of its desired effects and this 
may be attributed to the short half-life of 3-MMC (Shimshoni et al. 2015). 
Presently, 3-MMC is a controlled substance in several European countries, such 
as Sweden, France, Germany, Czech Republic, Poland and UK (Adamowicz et al. 
2016a; Backberg et al. 2015; Jamey et al. 2016; Shimshoni et al. 2015). In Portugal, 
the list of controlled substances was updated in 2012 (Lei nº 13/2012, de 26 de Março), 
which included thereafter 4-MMC, 3-MMC and isomers. The drug is also controlled in 
some countries outside of Europe, namely Israel and USA (Shimshoni et al. 2015). 
Table 1 Chemical structures of amphetamine, natural cathinone, and principal synthetic derivatives. 
Compound Chemical structure 
Amphetamine 
 
Cathinone 
 
Methcathinone 
(ephedrone) 
 
4-methylmethcathinone 
(mephedrone; 4-MMC) 
 
3-methylmethcathinone 
(metaphedrone; 3-MMC) 
 
Methylenedioxypyrovalerone 
(MDPV) 
 
4-methoxymethcathinone 
(methedrone) 
 
3,4-methylenedioxy-N-methylcathinone 
(methylone) 
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1.2. Physicochemical properties and analytical 
methods for identification 
Chemically, synthetic cathinones are analogues of the natural cathinone, which in 
turn is closely related to the amphetamines, with the addition of a ketone group at the 
-position of the amino alkyl chain, which is attached to the phenyl ring (Valente et al. 
2014). 3-Methylmethcathinone, also known as 2-(methylamino)-1-(3-
methylphenyl)propan-1-one, is a ring substituted cathinone with a methyl group 
attached to the third carbon atom of the phenyl ring (Zuba and Adamowicz 2016). Two 
enantiomers of 3-MMC exist, R-3-MMC and S-3-MMC, due to the chiral centre at the 
C-2 carbon of the propane side chain (WHO 2016). Similarly to cathinone, the S form 
of 3-MMC is expected to be more potent than the R form (WHO 2016) but this 
hypothesis awaits confirmation. 
As depicted in Fig.1, 3-MMC is available as a free base or as a hydrochloride salt 
that can be synthetized through the reaction of 3-methylbenzaldehyde (1) with ethyl 
magnesium bromide followed by oxidation with pyridinium chlorochromate on silica gel, 
and bromination with hydrobromic acid/hydrogen peroxide to obtain the bromo ketone 
(4). Then, the reaction with ethanolic methylamine will produce the 3-MMC free base 
(5). The free base can be converted into 3-MMC hydrochloride salt (6) by adding 
ethereal hydrogen chloride. The purity of 3-MMC can vary according to the purification 
steps performed during its synthesis (Power et al. 2011). Additional chemical properties 
of 3-MMC are presented in Table 2. 
Fig. 1 Synthesis of 3-methylmethcathinone (3-MMC). EtMgBr – ethyl magnesium bromide; PCC/Silica gel – 
pyridinium chlorochromate on silica gel; HBr – hydrobromic acid; H2O2 – hydrogen peroxide; MeNH2 – methylamine; HCl 
– hydrogen chloride. Adapted from Power et al. (2011). 
5 
 
Table 2 Physicochemical properties of 3-methylmethcathinone (3-MMC) hydrochloride salt. 
 3-MMC (hydrochloride salt) 
Chemical formula C11H15NO.HCl 
Molecular mass (g/mol) 213.7 
Melting point (ºC) 193.2 
Boiling point (ºC) (at 760 mm Hg) 280.5 
pKa 7.84 
Solubility 
Soluble in HBSS 
Slightly soluble in ethanol, 
dimethyl sulfoxide, and dimethyl 
formamide 
Partition coefficient (cLogP) 1.86 
Chemical Abstracts Service (CAS) 
number 
1246816-62-5 
Other chemical names 
3-methylmethcathinone; 
3-methyl-N-methylcathinone; 
metaphedrone; 
2-(methylamino)-1-(3-
methylphenyl)-1-propanone 
HBSS – Hank’s Balanced Salt Solution. Adapted from Shimshoni et al. (2015) and WHO (2016) 
There are several reports of the presence of cathinones in seized drug products 
and a number of analytical methods have been therefore developed for their 
identification, both in the seized materials and in the biological fluids of intoxicated 
individuals. In 2011, Power et al. (2011) synthetized and analysed 3-MMC through gas 
chromatography–mass spectrometry (GC-MS), infrared (IR) and nuclear magnetic 
resonance (NMR). In 2013, Christie et al. (2014) demonstrated that Raman 
spectrometry can distinguish between cathinones regioisomers, including 3-MMC. This 
is of great importance for the identification of drugs at airport security, where a fast and 
reliable identification is needed. Another great advantage of this method is the 
portability of the Raman microscope. In 2014, Strano Rossi et al. (2014) described an 
analytical approach to identify different types of new psychoactive substances (NPS) in 
seized material using GC-MS, liquid chromatography–high resolution mass 
spectrometry (LC-HRMS), and NMR. The most frequently used method for the 
identification of 3-MMC is liquid chromatography with different detectors, such as liquid 
chromatography tandem-mass spectrometry (LC-MS/MS) (Adamowicz et al. 2016a; 
Backberg et al. 2015; Maas et al. 2015; Shimshoni et al. 2015; Zuba and Adamowicz 
2016) and LC-HRMS (Frison et al. 2016). The second most frequently used method is 
GC-MS (Adamowicz et al. 2014; Institoris et al. 2015; Jamey et al. 2016; Maas et al. 
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2015; Odoardi et al. 2016; Zuba and Adamowicz 2016). Regarding the GC-MS 
methodology, Zuba and Adamowicz (2016) suggest that it is better fitted for analysis of 
seized drugs. As the GC-MS method is less sensitive than the LC-MS/MS method, the 
latter is more suitable for toxicological analysis of biological specimens (Zuba and 
Adamowicz 2016). The LC-HRMS method is one of the most specific and sensitive 
methods for hair sample analysis. The NMR method is mostly used when there is a 
need to distinguish between isomers (Odoardi et al. 2016; Strano Rossi et al. 2014) 
and can also be used for determining the purity of a substance. The identification of 
substances is crucial in forensics and for such purpose the combination of different 
methods provides a more reliable identification of the substance (Zuba and Adamowicz 
2016). 
1.3. Appearance, patterns of consumption and 
prevalence 
Like most “legal highs”, 3-MMC is usually sold online in the form of off-white 
crystals or white powder with a smell similar to lycorine (Jamey et al. 2016). It is 
labelled as a “research chemical” and/or “not for human consumption” (Institoris et al. 
2015). The price ranges from 11 € to 35 € per gram (Eurochemicals 2016; get-RC 
2016). Similarly to 4-MMC, consumption mostly occurs through insufflation (snorting) 
and orally (Adamowicz et al. 2016a; Backberg et al. 2015; Jamey et al. 2016; Sande 
2016; Shimshoni et al. 2015), but the intravenous injection of the drug has also been 
reported (Adamowicz et al. 2016a; Backberg et al. 2015; Jamey et al. 2016). 
In Germany, Marillier et al. (2017) analysed the purity of product samples 
donated by identified NPS users. From the 31 samples collected, 8 were positively 
confirmed for the presence of 3-MMC, although only 7 users admitted to be aware that 
the drug bought was 3-MMC. Those 8 samples had a range of purity between 51 % 
and 88 %. Reports from users of 3-MMC indicate drug administration doses often 
ranging from 50–250 mg, but higher amounts were occasionally described (up to 500 
mg), with repeated administrations to prolong the desired effects adding up to 
ingestions that could reach 2 g in a single session (Adamowicz et al. 2016a). This 
scenario is similar to that of 4-MMC, in which case, for the same reason, the users take 
between 150-250 mg in repeated administrations, resulting in ingestions of 0.5–1 g in a 
single session (Shimshoni et al. 2015). 
Studies conducted in Poland, Sweden, Hungary and Germany concluded that the 
users were mostly males with ages ranging from 17–50 years old (Adamowicz et al. 
2016a; Backberg et al. 2015; Institoris et al. 2015; Romanek et al. 2017). In Slovenia, 
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other investigations found no gender differences in the drug consumption patterns and, 
although the age of the respondents included in the sample ranged from 15–40 years 
old, most of them were still attending school (Sande 2016). 
The prevalence of these drugs is difficult to measure because little data is 
available and the existing information may not be accurate; questionnaires may not be 
reliable, as all too often consumers do not tell the truth about their consumption habits 
or do not know what they are buying. The same applies in case of intoxications without 
analytical confirmation. Some patterns of consumption are summarized in Table 3. 
From 2012 to 2013, Institoris et al. (2015) sampled suspected drug abusers in 
Hungary. Among the 1959 individuals in Budapest and the 472 individuals in South-
East Hungary (Csongrád County) that were confirmed positive for drug use, 3-MMC 
was detected in 0.97 % and 5.07 %, respectively (Institoris et al. 2015). In Germany, 
from 2010 to 2016, 81 intoxications with synthetic cathinones were reported by 
Romanek et al. (2017). From those, 13 tested positive for 3-MMC, 8 in 2014 and 5 in 
2015. The slight decrease observed in the detected number of cases might be a 
consequence of the implementation of the German narcotics law in December 2014 
(Maas et al. 2017), although the small size of the sample precludes robust conclusions. 
An impressive report by Adamowicz et al. (2016b) presents the results of the 
clinical drug-related cases analysed in the Institute of Forensic Research (Krakow, 
Poland) from 2012 to 2014. Succinctly, 3-MMC was detected in 50 of the 112 cases 
that were positive for NPS, being the most prevalent drug. Eleven cases occurred in 
2013 and 39 cases in 2014, supporting the increasing interest in the drug (Adamowicz 
et al. 2016b). The drug prevalence reported in this study is higher than that reported by 
Institoris et al. (2015). This could be explained by the small sample size in the Polish 
study, which may result in sample bias. Another explanation might be that the sample 
from Poland only includes NPS, while the sample from Hungary includes both classic 
drugs and NPS. 
From May to October 2014, Sande (2016) employed a questionnaire to 249 drug 
users, in Slovenia. From those, 67.9 % of the users said that they had tried 3-MMC, 
while one-third of users admitted having used the drug in the past month (Sande 2016). 
As this questionnaire was performed online, it leaves out NPS consumers that do not 
have internet access. 
The interest in a particular drug can also be measured in online forums. Ledberg 
(2015) studied the interest in 8 NPS before and after scheduling. The author used the 
data extracted from the Flashback Forum, a Swedish Internet discussion forum, and 
measured the interest by counting the number of posts per day, 180 days before and 
after the respective drug being prohibited. For 3-MMC, the interest before scheduling 
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hit a maximum around 80 posts per day (mean of 20 post per day) and around 5 posts 
per day after scheduling (mean of 3.1 posts per day) (Ledberg 2015). This is consistent 
with the pattern of analytically confirmed exposure to 3-MMC found in the Swedish 
STRIDA project (Swedish early‐warning system on NPS), that decreased when the 
substance was legally framed (Backberg et al. 2015). Drug forums may also be 
important to obtain information on substance dose reported by users (Ledberg 2015), 
which may be of great importance to adopt measures in case of intoxications or to plan 
a study on the toxicity of the selected drug. 
Table 3 Patterns of consumption of 3-methylmethcathinone (3-MMC). 
Year Location n 
Age 
(years) 
Individuals 
consuming 
3-MMC (%) 
Consumed 
dose (g) 
Reference 
2012 – 2013 
Budapest 1959 
18 – 50 
1.0 
 
Institoris et 
al. (2015) Csongrád 
Country 
472 5.1 
2012 – 2014 Sweden 786 17 – 49 6.4 0.5 – 2 
Backberg et 
al. (2015) 
2012 – 2014 Poland 112 16 – 50 44.6  
Adamowicz 
et al. 
(2016b) 
2014 Slovenia 249 15 – 40 1 67.9 1.5 
Sande 
(2016) 
2010 – 2016 
Southern 
Germany 
81 17 – 49 16.0  
Romanek et 
al. (2017) 
1 Mostly students 
1.4. Biological effects 
Most information on biological effects in humans derives from case reports of 
intoxicated individuals that are admitted to the emergency room, from online 
questionnaires, or self-reports of consumers of 3-MMC, but even these data are 
scarce. 
The desired effects of 3-MMC are euphoria, excitement, high energy levels, 
stimulation (rushing), happiness, awareness of senses, and appreciation of music 
(Adamowicz et al. 2016a; Adamowicz et al. 2014). As with amphetamines and other 
stimulant drugs of abuse, the social effects consist of improved social skills and 
feelings of empathy (Adamowicz et al. 2016a) but chronic abuse may trigger 
deterioration of relationships with family, partner and friends (Sande 2016). 
Among the adverse effects of 3-MMC are verbosity, stuttering, fatigue, agitation, 
aggression, uncoordinated movements, and tachycardia (Adamowicz et al. 2016a). 
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Concentration difficulties, tingling in the arms and legs, hyponatremia, diaphoresis, 
seizures, hyperthermia, and rhabdomyolysis have been known to occur but with lower 
frequency (Backberg et al. 2015; Sande 2016). 
Other effects that have been reported include hypertension, dilated pupils, 
hallucinations, fear, anxiety, depression, disorientation, slurred speech, strange 
behaviour, unsteady gait, and staggering but these effects could not be unequivocally 
attributed to 3-MMC as other substances were co-ingested (Adamowicz et al. 2016a; 
Backberg et al. 2015; Sande 2016). Maas et al. (2015) described the case of a user 
driving under the influence of methadone, 3-MMC, lorazepam and, 2-ethylidene-1,5-
dimethyl-3,3-diphenylpyrrolidine (EDDP) who presented deficient concentration, 
delayed reaction time, problems with balance and coordination, impaired fine motor 
skills, washed out pronunciation, and disorientation, which cannot be attributed to 3-
MMC alone. Reported case reports from fatal and non-fatal intoxications are shown in 
Tables 4 and 5. 
1.5. Pharmacokinetics 
Little data is available on the pharmacokinetics of 3-MMC. To the best of our 
knowledge no human studies are documented in the literature and only one study 
using animals is available (Shimshoni et al. 2015). The pharmacokinetic features of 3-
MMC are described below and based on the work of Shimshoni et al. (2015) in pigs. 
Although this animal study is the only one so far reported, caution should be taken 
when interpreting the results due to the small sample size (n = 6) (Shimshoni et al. 
2015). 
1.5.1. Absorption 
In this study, 3-MMC was only administered orally and through intravenous 
injection. After a single oral dose of 3 mg/kg of the hydrochloride salt form of the drug, 
the peak plasma concentration of 3-MMC (Cmax = 27 µg/L) occurred at 5–10 min 
(Shimshoni et al. 2015). Only 7 % of the drug was absorbed, after oral administration. 
Absorption mostly occurred in the first 12 min (corresponding to more than 80 % of the 
absorbed drug). The low oral bioavailability observed may explain the preferred use of 
3-MMC through insufflation (Shimshoni et al. 2015). This may indicate that 3-MMC 
suffers first-pass metabolism before reaching systemic circulation (Shimshoni et al. 
2015). After a single intravenous dose of 0.3 mg/kg in saline of the hydrochloride salt 
form of the drug, almost none of the drug was detected after 4 h (Shimshoni et al. 
2015). 
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Table 4 Case reports of non-fatal intoxications involving 3-MMC. 
Year Local 
Cases 
(n) 
Sex/Age 
(years) 
Intoxication symptoms Drug Concentration Reference 
2012 - 2014 Sweden 50 
M (n = 38); 
F (n = 12)/ 
17-49 
Tachycardia (≥ 100/min); Agitation; 
Hypertension (systolic blood pressure ≥ 
140 mmHg); Reduced level of 
consciousness (RLS > 2); Dilated pupils; 
Hallucinations; Hyponatremia (136 mmol 
sodium/L); Diaphoresis; Seizures; Clinical 
significant hyperthermia (39 °C); 
Rhabdomyolysis (25 IU CK/L, 3000 μg 
myoglobin/L) 
0.002–1.5 µg/mL of 3-MMCs;  
0.007 – 290 µg/mL of 3-MMCu 
Backberg 
et al. 
(2015) 
2012 - 2014 Poland 112 
M (n = 102); 
F (n = 10)/ 
16 - 50 
Verbosity; Slurred speech; Strange 
behaviour; Unsteady gait; Staggering 
< 0.001–1.6 µg/mL of 3-MMCb 
Adamowicz 
et al. 
(2016b) 
2013 - 2015 Poland 95 
M (n = 89); 
F (n = 6)/ 
17 – 50 
Gaiety; Verbosity; Stuttering; Fatigue; 
Agitation; Aggression; Uncoordinated 
movements; Tachycardia (100 bpm) 
0.003–0.2 µg/mL of 3-MMCb 
Adamowicz 
et al. 
(2016a) 
2015 - 2016 
 
France 
 
3 
 
F/22 Confusion; Somnolence; Myosis; GS = 10 
0.3 µg/mL of 3-MMCp;  
0.02 µg/mL of 5-MAPBp;  
0.1 µg/mL of methadone 
Turcant et 
al. (2017) 
M/35 
Agitation; Hypertension; Chest pain; 
Tachycardia 
0.007 µg/mL of 3-MMCp;  
2.4 µg/mL of 3-MMCu 
M/29 Hallucinations; Tachycardia 0.2 µg/mL of 3-MMCb 
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Table 4 Case reports of non-fatal intoxications involving 3-MMC (continuation). 
Year Local 
Cases 
(n) 
Sex/Age 
(years) 
Intoxication symptoms Drug Concentration Reference 
2015 - 2016 
 
France 
 
3 
 
M/23 Seizures; GS = 3 
1.6 µg/mL of 3-MMCp; 0.9 µg/mL 
of 4-MECp; 1.2 µg/mL of MXEp; 
141 µg/mL of 3-MMCu; 61 µg/mL 
of 4-MECu; 39 µg/mL of MXEu 
Turcant et 
al. (2017) M/37 Agitation; Mydriasis; Tachycardia 
0.06 µg/mL of 3-MMCp; 0.2 µg/mL 
of 4-MECp; 0.01 µg/mL of MEXp; 
0.1 µg/mL of MDMAp; 13 µg/mL of 
3-MMCu; 85 µg/mL of 4-MECu; 0.9 
µg/mL of MEXu; 5.6 µg/mL of 
MDMAu; 0.3 µg/mL of MDAu 
M/30 Coma; Myosis; Bradypnea; GS = 3-5 
0.2 µg/mL of 3-MMCp; 200 µg/mL 
of GHBp; 41.6 µg/mL of 3-MMCu; 
685 µg/mL of GHBu 
2015 Germany 1 M/34 
Deficient concentration; Delayed reaction 
time; Problems with balance and 
coordination; Impaired fine motor skills; 
Washed out pronunciation; Disorientation 
0.1 µg/mL of methadones; 0.006 
µg/mL EDDPs; 0.03 µg/mL of 
lorazepams; 0.04 µg/mL of 3-
MMCs 
Maas et al. 
(2015) 
2016 Italy 1 M  0.03 µg/mL of 3-MMCph 
Frison et 
al. (2016) 
2014 - 2016 Germany 2 
F/26 
Depressive mood; Pupil with slow reaction 
to light 
0.04 µg/mL of 3-MMCs Maas et al. 
(2017) 
  0.01 µg/mL of 3-MMCs 
RLS – Reaction level scale; CK – Creatine kinase; EDDP – 2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine; GS – Glasgow score; 5-MAPB – 5-(2-Methylaminopropyl)benzofuran; 4-MEC – 
4-Methylethcathinone; MXE – methoxetamine; MDMA – 3,4-Methylenedioxymethamphetamine; MDA – 3,4-methylenedioxyamphetamine; Bpm – beats per minute 
s Serum; u Urine; b Blood; p Plasma; ph Pubic hair  
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1.5.2. Distribution 
3-MMC had a total clearance of 199 L/h and a volume of distribution of 240 L 
(Shimshoni et al. 2015). The total clearance determined in this study represents more 
than the sum of liver and kidney blood flow (88 L/h) in pigs that weight 30-40 kg 
(Shimshoni et al. 2015), which can mean that there are additional elimination sites or 
mechanisms besides hepatic and renal metabolism. The large volume of distribution 
may be due to low protein binding and probably due to active transportation into the 
tissue compartment (Shimshoni et al. 2015). 
1.5.3. Metabolism 
The metabolism of 3-MMC is not fully disclosed, but based on information 
obtained from the analysis by LC-HRMS of pubic hair it is known that 3-methylepedrine 
and 3-methylnorephedrine are metabolites of the drug (Frison et al. 2016). A 
hypothetical metabolic human pathway was proposed and presented in Fig. 2. 
Fig. 2 Hypothetic metabolism of 3-methylmethcathinone (3-MMC) into 3-methylnorephedrine through β-keto-
reduction [1] followed by N-demethylation [2] into 3-methylnorephedrine. Adapted from Frison et al. (2016). 
The relevance of the metabolism for the pharmacological and toxicological profile 
of 3-MMC is yet to be revealed. Similar to 3-MMC, the metabolic pathway of 4-MMC is 
not fully known in humans (Khreit et al. 2013). It is known that nor-mephedrone, nor-
dihydro mephedrone, hydroxytolyl mephedrone, and nor-hydroxytolyl mephedrone, 4-
carboxymephedrone and 4-carboxydihydromepedrone are metabolites of 4-MMC 
excreted in urine (Ribeiro et al. 2012).  
1.5.4. Excretion 
In pigs, the pharmacokinetics of 3-MMC appears to follow a one-compartment model 
(Shimshoni et al. 2015). The elimination half-life of 3-MMC was 0.83 h, corroborating the 
values achieved for total clearance and distribution volume. Most of the dose was excreted 
after 4 h of administration, either when administered through injection or orally (Shimshoni 
et al. 2015). The elimination rate constant of 3-MMC was 0.84 h-1 (Shimshoni et al. 2015). 
This rapid elimination rate may justify the short psychoactive effects and, consequently, the 
need to repeat oral administrations during consumption sessions (WHO 2016). 
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1.6. Toxicity 
1.6.1. Lethal case reports 
Few fatal intoxications have been reported due to the consumption of 3-MMC. 
The cases reported so far were thirteen and all occurred in Europe (WHO 2016). The 
available information about these cases is summarized in Table 5. 
In Sweden, two deaths occurred from 2012 to 2014; both patients co-ingested 
other drugs (Backberg et al. 2015). In the UK, one individual committed mechanical 
suicide under the influence of 3-MMC, venlafaxine, and an unknown substance 
(suspected of being cocaine and/or an amphetamine) (Elliott 2016). Suicide has 
already been associated with the use of other synthetic cathinones (Elliott and Evans 
2014). In Poland, 5 fatal cases involving 3-MMC were described (Adamowicz et al. 
2016a). The first case involved 3-MMC and MDMA. The second case involved 3-MMC 
and 5-APB (5-(2-Aminopropyl)benzofuran). The third case also involved 3-MMC and 5-
APB, but different concentrations of the drugs were quantified in blood (Tables 5 and 
6). The fourth case involved 3-MMC and 25I-NBOMe (2-(4-Iodo-2,5-dimethoxyphenyl)-
N-[(2-methoxyphenyl)methyl]ethanamine). The last case involved 3-MMC and tramadol 
at therapeutic concentration (Adamowicz et al. 2016a). In Norway, Karinen et al. (2014) 
described the fatal intoxication of a young man with AH-7921 (3,4-Dichloro-N-{[1-
(dimethylamino)cyclohexyl]methyl}benzamide), 2-FMA (2-fluoromethamphetamine), 3-
MMC, codeine, codeine-6-glucuronidie, and acetaminophen. 
Only two deaths were attributed to 3-MMC alone. One of these deaths was 
reported in Italy (Rojek et al. 2015). The other one was described by Bottinelli et al. 
(2016) and occurred in France. All the other fatal cases reported involved the 
administration of the drug in association. Accordingly, Bottinelli et al. also described 
two deaths in which 3-MMC was detected along with other drugs; in the first one, 3-
MMC was co-ingested with alcohol, paracetamol, paroxetine, sildenafil, and 4-
methylethcathinone (4-MEC) (2016); in the second case, the death of a 32-year old 
individual was attributed to 3-MMC and GHB (2017). These two drugs were also 
involved in the cause of death of a 69-year old man, in France (Jamey et al. 2016). 
The majority of the deaths involving 3-MMC (8 deaths out of 13) occurred with 
the co-ingestion of other drugs (Adamowicz et al. 2016a; Adamowicz et al. 2014; 
Backberg et al. 2015; Bottinelli et al. 2017; Bottinelli et al. 2016; Jamey et al. 2016; 
Karinen et al. 2014). Of these, 5 deaths were attributed to drugs used for medical 
purposes (Adamowicz et al. 2016a; Bottinelli et al. 2016; Jamey et al. 2016; Karinen et 
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al. 2014). In the two deaths that involved 3-MMC alone, blood concentrations of 0.249 
µg/mL (Bottinelli et al. 2016) and 4.4 µg/mL (Rojek et al. 2015) were reported. Because 
the number of fatal cases is relatively small, and because only two of these cases 
involved 3-MMC alone, it is not possible to draw any conclusion about potentially toxic 
and/or lethal 3-MMC concentrations. Also, postmortem findings are highly influenced 
by the circumstances of the intoxication, time elapsed from drug intake, and whether 
life support measures were adopted or not. For these reasons, the reported drug 
blood/tissue concentrations are highly discrepant among intoxicated individuals (Table 
5 and 6). 
1.6.2. Mechanisms of toxicity 
There are no studies elucidating the mechanisms of toxicity of 3-MMC. In the 
study conducted by Shimshoni et al. (2015) in pigs, no changes in serum biochemical 
markers were found after the administration of 3-MMC. Some of these markers were 
cholesterol, creatinine, total protein, and urea. The authors also stated no drug-related 
mortality or morbidity and did not detect any gross pathological or abnormal 
histopathological findings (Shimshoni et al. 2015). The tissues analysed were the heart, 
skeletal muscles (diaphragm, intercostal, triceps, and others), lungs, pancreas, liver, 
kidney, spleen, brain and small intestine. 
In the literature, the toxicological data regarding synthetic cathinones is scarce. It 
is expected that some of the mechanisms are similar to those of amphetamines, as 
cathinone and synthetic cathinones have similar structures (Valente et al. 2014). From 
the few information available for synthetic cathinones, it is noted that 4-MMC produces 
concentration-dependent cytotoxicity and impairment of mitochondrial respiration in 
SH-SY5Y cells at concentrations of 1 mM and 2 mM, respectively (Hollander et al. 
2015). By virtue of the similarity between both drugs, one can hypothesise that 3-MMC 
could likely induce the same effects (Valente et al. 2014). 
It is well known that amphetamines cause hyperthermia, which can increase the 
formation of ROS and RNS (reactive species of oxygen and nitrogen, respectively) 
species (Dias da Silva et al. 2014a). As 3-MMC also causes hyperthermia, it is also 
likely to occur formation of ROS and RNS. Backberg et al. (2015) described a fatal 
case where the patient was hyperthermic after 20 h of administration (40.9 ºC), an 
effect that persisted even after sedation, external cooling and administration of cold 
fluids. The patient also had metabolic acidosis and rhabdomyolysis, which 
compromised his renal function. Six days after the admission the patient died 
(Backberg et al. 2015). 
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Table 5 Deaths related to 3-methylmethcathinone (3-MMC). 
Year Local 
Cases 
(n) 
Sex/Age 
(years) 
Cause of death/ 
autopsy findings 
Postmortem toxicological analysis Reference 
2012 – 2014 Sweden 2 
M Polydrug abuse  
Backberg 
et al. 
(2015) M/25 Polydrug abuse 
3-MMC: 0.002 µg/mL s; 0.09 µg/mL u. Small concentration of ethanol 
metabolites u. 
2013 UK 1  Mechanical suicide 
1.1 µg/mL of 3-MMC fb; 1.6 µg/mL of venlafaxine fb; 2.8 µg/mL O-
desmethylvenlafaxine fb 
Elliott 
(2016) 
2013 – 2015 Poland 4 
M Polydrug abuse < 0.001 µg/mL of 3-MMC; 0.03 µg/mL of MDMA 
Adamowicz 
et al. 
(2016a) 
 Polydrug abuse 0.02 µg/mL of 3-MMC; 0.1 µg/mL of 5-APB 1; 3.4 mg/g of Katelin s 
M 
Acute respiratory 
failure caused by 
massive pneumonia/ 
Multiple organ failure 
0.01 µg/mL of 3-MMC b; 0.003 µg/mL of 25I-NBOMe b 
  0.003 µg/mL of 3-MMC b; 0.6 µg/mL of tramadol b 
2014 Norway 1 
M/early 
twenties 
Poly drug abuse      
Oedematous lungs 
0.002 µg/mL of 3-MMC pwb; 0.4 µg/mL of AH-7921 pwb; 0.4 µg/mL of 
codeine pwb; 0.8 µg/mL C6G pwb; 19 µg/mL of acetaminophen pwb; 0.007 
of µg/mL 2-FMA pwb 
Karinen et 
al. (2014) 
2014 Poland 1 M/20 Polydrug abuse 1.6 µg/mL of 3-MMC b; 5.6 µg/mL of 5-APB b 
Adamowicz 
et al. 
(2014) 
2015 Italy 1  3-MMC intoxication 4.4 µg/mL of 3-MMC b 
Rojek et al. 
(2015) 
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Table 5 Deaths related to 3-methylmethcathinone (3-MMC) (continuation). 
Year Local 
Case 
(n) 
Sex/Age 
(years) 
Cause of death/ 
Autopsy findings 
Postmortem toxicological analysis Reference 
2016 France 2 M/thirties 
Polydrug abuse 
0.08 µg/mL of 3-MMC b; 180 µg/mL of alcohol b; 0.1 µg/mL of 
paracetamol b; 0.1 µg/mL of paroxetine b; 0.08 µg/mL of sildenafil b; 0.1 
µg/mL of 4-MEC b 
Bottinelli et 
al. (2016) 
3-MMC intoxication 0.2 µg/mL of 3-MMC b 
2016 France 1 M/69 Polydrug abuse 
3-MMC: 0.33 µg/mL pb; 0.9 µg/mL cb; 29.0 µg/mL u; 1.5 µg/mL gc; 0.6 
µg/mL bl; 206.7 ng/mg h. GHB 1: 576 µg/mL pb; 630 µg/mL cb; 719 
µg/mL u; 2671 µg/mL gc; 909 µg/mL bl; 96.3 ng/mg h. Pseudoephedrine: 
0.03 µg/mL pb; 0.08 µg/mL cb; 1.1 µg/mL u; 0.1 µg/mL gc; 0.05 µg/mL bl; 
0.2 ng/mg h. 
Jamey et 
al. (2016) 
2016 France 1 M/32 3-MMC intoxication 
3-MMC: 0.2 µg/mL pb; 0.6 µg/mL cb; 3.0 µg/mL vh; 29.7 µg/mL u; 1.3 
µg/mL bl. GHB:  35.7 µg/mL pb; 25.0 µg/mL cb; 8.8 µg/mL u; 12.4 µg/mL 
bl. 
Bottinelli et 
al. (2017) 
2014 – 2015 Germany 1  
Cardiac 
arrest/Cerebral 
oedema/Brain death 
 
Romanek 
et al. 
(2017) 
3-MMC – 3-Methylmethcathinone; MDMA – 3,4-Methylenedioxymethamphetamine; 5-APB – 1-Benzofuran-5-ylpropan-2-amine; katelin – potassium chloride; 25I-NBOMe – 2-(4-Iodo-2,5-
dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine; AH-7921 – 3,4-Dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}obenzamide; C6G – Codeine-6-glucuronide; 2-FMA – 2-
Fluoromethamphetamine; 4-MEC – 4-Methylethcathinone; GHB – γ-Hydroxybutyric acid; 
pwb Peripheral whole blood; b Blood; pb Peripheral blood; s Stomach; cb Cardiac blood; u Urine; gc Gastric content; bl Bile; h Hair; fb Femoral blood; vh Vitreous humor 
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In comparison, the hyperthermia caused by MDMA is frequently responsible for fatal 
complications, including rhabdomyolysis, acute renal failure, disseminated 
intravascular coagulation (DIC), multiple organ failure, and acidosis (Henry et al. 1992; 
Kalant 2001; Kendrick et al. 1977). Some of these events were observed in the fatal 
case described by Backberg et al. (2015). This may suggest that 3-MMC shares some 
of the mechanisms of toxicity with MDMA. 
1.7. Factors affecting the stimulant/toxicological 
effects 
1.7.1. Dose/concentration 
There are no studies in humans with 3-MMC that describe the relation between 
the administered dose and the elicited stimulant/toxicological effects. The only study 
containing the dose information was reported by Backberg et al. (2015) and describes 
the clinical features observed in patients positive for 3-MMC. Nevertheless, by virtue of 
the broad interval of doses mentioned (0.5–2 g), no associations between these and 
the reported symptoms could be established. The same applies to the blood 
concentrations found. 
In the three-year review of Adamowicz et al. (2016b) mentioned above, the data 
collected from medical and police notes concerning 50 cases involving 3-MMC was 
divided in two groups: in the first group, information of the cases in which 3-MMC was 
detected alone was considered; in the second group, 3-MMC was detected along with 
other drugs. Regarding the first group, the blood concentration range observed for 
asymptomatic users was higher (0.01 µg/mL – 0.2 µg/mL) than that achieved for 
individuals presenting 3-MMC-induced symptoms (0.01 µg/mL – 0.02 µg/mL). This was 
attributed to the fact that symptomatic individuals were mostly first time users, while the 
same was not observed for asymptomatic users. In the second group, the same 
tendency was observed (users with no symptoms: 0.001 µg/mL – 0.2 µg/mL; users with 
symptoms: 0.001 µg/mL – 0.06 µg/mL) but in this case results were more difficult to be 
interpreted, since polydrug abuse was at play. This will be further discussed below. 
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Table 6 Blood concentrations of 3-methylmethcathinone (3-MMC) in fatal and non-fatal intoxications.  
Dose 
(g) 
Concentration 
(µg/mL) 
Concentration 
post-mortem 
(µg/mL) 
Intoxication Reference 
  
0.002 Fatal Karinen et al. (2014) 
  
1.6 Fatal Adamowicz et al. (2014) 
0.5 – 2 0.002 – 1.5 
 
Non-fatal Backberg et al. (2015) 
 
0.04 
 
Non-fatal Maas et al. (2015) 
 
< 0.001 – 1.6 
 
Non-fatal Adamowicz et al. (2016b) 
 
0.003 – 0.2 
 
Non-fatal 
Adamowicz et al. (2016a) 
  < 0.001 Fatal 
  0.02 Fatal 
  0.01 Fatal 
  0.003 Fatal 
 0.02  Non-fatal 
  
0.3 Fatal Jamey et al. (2016) 
  
0.08 Fatal 
Bottinelli et al. (2016) 
  0.2 Fatal 
  
4.4 * Fatal Rojek et al. (2015) 
  
1.1 Fatal Elliott (2016) 
  0.2 Fatal Bottinelli et al. (2017) 
In cases marked with *, the only drug involved was 3-methylmethcathinone (3-MMC). 
1.7.2. Route of administration 
Stimulant/toxic effects are dependent on the route of administration. As 
mentioned above, the preferred route of administration is through insufflation, which 
may be explained by the low oral bioavailability (Shimshoni et al. 2015). Rapid onset of 
the effects and cultural preferences may also help explain the use of this administration 
route. After insufflation, the first effects appear between 20–30 min and the peak 
effects occur after 50 min, lasting up to 3–4 h, which is why users repeat administration 
(two or three times, every 2 h) to prolong the effects (Adamowicz et al. 2016a). This is 
similar to 4-MMC, for which the first effects appear 15–45 min after administration, and 
last up to 4–5 h (Shimshoni et al. 2015). 
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1.7.3. Polydrug abuse 
Frequently, 3-MMC is consumed with other drugs and it is difficult to describe 
how this abuse pattern affects the induced stimulant/toxic effects (Adamowicz et al. 
2016a) because there are drug-drug interactions that are unknown. Accordingly, most 
of the symptoms reported cannot be attributed to 3-MMC alone, although it is usual that 
polydrug users have less severe effects than those who only consume 3-MMC 
(Adamowicz et al. 2016b). This can be explained due to the phenomenon of tolerance, 
as it is common that polydrug users are frequent drug abusers. 
1.7.4. Interaction with therapeutic drugs 
There are five cases described in the literature involving 3-MMC and therapeutic 
drugs, which were previously mentioned and are presented in Table 5. Overall, it is 
difficult to draw conclusions on the emerging interactions because all too often there 
are other drugs of abuse present. Contrary to the cases in which other types of drugs 
were detected, pharmaceuticals are present at very low levels. 
Adamowicz et al. (2016a) briefly described two fatal cases with 3-MMC and 
therapeutic drug interactions. Among the co-abused drugs were tramadol and 
potassium chloride (Katelin) (Table 5). 
Karinen et al. (2014) described a fatal case with 3-MMC, codeine, and 
acetaminophen. The man was prescribed a drug combination of codeine and 
acetaminophen (30 mg codeine/400 mg acetaminophen) after a minor traffic accident. 
He took 6 of these pills and some 3-MMC powder he bought online. The results from 
toxicological analysis of peripheral whole blood can be found in Table 5. Although 
codeine and acetaminophen were prescribed in therapeutic doses and low 
concentrations were found in blood, other non-therapeutic drugs were taken and may 
have also contributed for the fatality (Karinen et al. 2014). 
Bottinelli et al. (2016) briefly described a case with 3-MMC, acetaminophen, 
sildenafil and paroxetine (Table 5). Jamey et al. (2016) described a case of 3-MMC and 
pseudoephedrine. The toxicological analysis revealed 0.3 µg/mL of 3-MMC, 576 µg/mL 
of GHB (gamma-hydroxybutyric) and 0.03 µg/mL of pseudoephedrine (Jamey et al. 
2016). As the concentration of pseudoephedrine is much lower than the concentration 
of 3-MMC and GHB, the author concluded that it was likely that the death occurred 
because of the interaction of 3-MMC and GHB. It was hypothesized that the trace of 
pseudoephedrine was derived either from a clinical treatment or from the illicit 
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manufacture of 3-MMC, since pseudoephedrine is also a precursor in 
methamphetamine and methcathinone synthesis (Jamey et al. 2016). 
1.7.5. Environmental conditions 
When the consumption of the drug occurs in nightclubs, where the atmosphere is 
hot and crowded and the ventilation bad, it is expected a much more severe 
detrimental effect, as these conditions aggravate the hyperthermia and diaphoresis 
elicited by 3-MMC (Backberg et al. 2015). Accordingly, a body temperature as high as 
40.9 ºC was observed in an individual who took the drug in a hot environment. 
This is consistent with what is known for the related drug MDMA, it was reported 
that when the environmental temperature was below 22 ºC the rats tended to develop 
hypothermia, and when the temperature was above 28 ºC, the hyperthermia became 
life-threatening (Capela et al. 2009). 
1.7.6. Individual characteristics of the 
consumer 
There are several characteristics of the consumer that will influence the drug-
associated risks (Carvalho et al. 2012). The main characteristics of the consumer that 
may increase the susceptibility to the acute effects of the drug are age, ethnicity, 
metabolic polymorphisms, and gender (Carvalho et al. 2012). To the best of our 
knowledge, there is no human study that relates these characteristics with the effects 
caused by synthetic cathinones. Since cathinone and synthetic cathinones have similar 
structures to amphetamines, it is expected that the influence of these factors to be 
similar (Valente et al. 2014). 
1.7.6.1. Age 
The consumption of NPS is mainly associated with younger age groups 
(EMCDDA 2016). It is known that age can affect the expression of enzymes involved in 
the metabolism of drugs (Parkinson et al. 2004). It is also known that adolescents have 
a higher metabolic rate of the enzymes involved in the metabolism (Parkinson et al. 
2004), thus having reduced sensitivity to the psychoactive effects of certain drugs, for 
example, amphetamines (Carvalho et al. 2012). For this reason, it is expected that 
younger individuals consume more drug than older individuals to obtain the same 
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desired effects (Wiley et al. 2008). This might mean that they are more susceptible to 
intoxications. 
1.7.6.2. Metabolism and enzymatic 
polymorphisms 
Polymorphic expression of metabolic enzymes is known to highly influence the 
metabolism and toxicity of amphetamines. For example, for MDMA, it is known that 
CYP2D6 is a major enzyme involved in the oxidative metabolism (Carvalho et al. 
2012). Therefore, it is expected that individuals carrying deficient alleles for the enzyme 
to be more susceptible for acute toxic effects (Carvalho et al. 2012). As CYP2D6 has 
various variants in different populations, the ethnicity of a user is expected to affect the 
toxicity of amphetamines (Ramamoorthy et al. 2002; Tucker et al. 1994). 
1.7.6.3. Ethnicity 
Ethnicity can influence the effects of drugs because of genetic variation, different 
dietary habits and lifestyle factors (Carvalho et al. 2012). As mentioned above, 
mutations on the genetic code can be the reason for the increase of stimulant/toxic 
effects, depending on the genotype (Haile et al. 2009). Some of these genetic 
polymorphisms can profoundly affect the expression and/or activity of membrane 
transporters and other proteins, as such that intervene in the metabolism of the drug, 
impacting the toxicological expression of the drug (Carvalho et al. 2012). 
1.7.6.4. Gender 
The gender can also affect the stimulant/toxic effects of a drug. It is known that 
women are more susceptible to the toxic effects of MDMA (Liechti et al. 2001; 
Parkinson et al. 2004), probably because they have a lower metabolic capacity 
(Carvalho et al. 2012). However, men seem more susceptible to hyperthermia and 
therefore to the toxic effects of amphetamines than women, thus experiencing more 
severe symptoms (Miller and O'Callaghan 1994). This most likely occurs because men 
have a higher metabolic rate and higher drug consumption patterns (EMCDDA 2010a). 
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By virtue of the increasing frequency of use of synthetic cathinones, research to 
elucidate their toxicological effects is of utmost importance, as the vast majority of 
these drugs rarely endure safety and quality control procedures. In addition, as soon as 
a substance becomes prohibited, new derivatives are synthesized to fill its gap, which 
frequently results in numerous severe adverse events and even deaths. With the 
intense rate of production of NPS, it is difficult to follow their emergence in the drug 
scene with satisfactory knowledge on the mechanisms of toxicity. Notwithstanding, this 
information is vital to elucidate users about the serious risks involved in the 
consumption of such substances. 
Since oral ingestion is the major administration route for these stimulants, the 
liver represents one of the main targets of their toxicity, largely due to the first passage 
effect. Also, due to the important role of liver in metabolism, it is possible that the drug 
may undergo bioactivation with production of more toxic metabolites, compromising the 
functionality of the organ and, therefore, the overall health of the abuser. 
In this context, and since there is a significant lack of information on the 
underlying mechanisms of toxicity of 3-MMC but its consumption has been increasing, 
the current study aimed to:  
i) Analyse the potential in vitro hepatoxicity of 3-MMC, using primary rat 
hepatocytes;  
ii) Elucidate the contribution of the metabolism by different isoforms of the 
cytochrome P450 to the observed toxicity;  
iii) Clarify the toxicological mechanisms involved in the observed 
hepatotoxic effects, by evaluating a range of oxidative stress, mitochondrial integrity, 
and energetic balance endpoints, and the mode of cell death. 
iv) Characterize the metabolic profile of 3-MMC by gas chromatography-
mass spectrometry (GC-MS) for the identification and/or quantification of 3-MMC and 
metabolites. 
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3.1. Cytotoxic profile of 3-methylmethcathinone (3-
MMC) 
3.1.1. Chemicals 
The hydrochloride salt of 3-MMC was purchased online from the Sensearomatic 
website (http://sensearomatic.net, currently unavailable), in March 2016. Unless stated 
otherwise, all other chemicals were purchased from Sigma-Aldrich (Lisbon, Portugal) 
and all the cell culture reagents from Gibco® (Alfagene, Lisbon, Portugal). 
3.1.2. Animals 
Male Wistar Han rats with a body weight of 150–250 g were purchased from 
Charles River Laboratories (Barcelona, Spain). The animals, kept under controlled 
temperature (20 ± 2 °C), humidity (40–60 %), and lighting (12 h-light/dark cycle) 
conditions, were fed with standard rat chow and tap water ad libitum. Isolation of 
hepatocytes was always conducted between 8:00 and 10:00 a.m. Surgical procedures 
were performed after rat anaesthesia and analgesia induced by an intraperitoneal 
injection of a combination of 20 mg/kg xylazine (Rompun® 2 %, Bayer HealthCare, 
Germany) and 100 mg/kg ketamine (Clorketam® 1000, Vétoquinol, France), and 
maintained through inhalation of isoflurane vapour (IsoVet® 1000 mg/g, B. Braun 
VetCare, Germany). This study was approved by the local committee for the welfare of 
experimental animals and performed in accordance with national legislation by 
investigators accredited for laboratory animal use by the national authority Direção 
Geral de Alimentação e Veterinária (DGAV), under the terms of the Law No. 1005/92, 
of 23rd October, Article 3, paragraph b, subparagraph iii). 
3.1.3. Isolation of primary rat hepatocytes 
Isolation of hepatocytes was performed using a modified two-step perfusion of 
the liver, as previously described by Moldeus et al. (1978), with some modifications. 
The liver was perfused in situ via the vena portae, firstly with a sterile EGTA-buffer at 
37 °C, for approximately 10–15 min. The chelator promotes the cleavage of the hepatic 
desmosomes through calcium sequestration. The EGTA-buffer consisted of 248 mL 
glucose solution (9 g/L d-glucose), 40 mL Krebs-Henseleit-buffer (60 g/L NaCl, 1.75 g/L 
KCl, and 1.6 g/L KH2PO4; adjusted to pH 7.4), 40 mL HEPES-buffer I (60 g/L HEPES; 
adjusted to pH 8.5), 30 mL MEM non-essential amino acid solution (100x), 30 mL MEM 
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Amino Acids (10x) solution, 4 mL glutamine solution (7 g/L l-glutamine), and 1.6 mL 
EGTA-solution (47.5 g/L EGTA added of NaOH until total dissolution; adjusted to pH 
7.6). Subsequently, hepatic collagen was hydrolysed by liver perfusion for 10–15 min 
with a sterile collagenase buffer, at 37 °C. The collagenase buffer consisted of 155 mL 
glucose solution, 25 mL Krebs-Henseleit-buffer, 25 mL HEPES-buffer I, 15 mL MEM 
non-essential amino acid solution (100x), 15 mL MEM amino acids (10x) solution, 10 
mL of CaCl2 solution (19 g/L CaCl2.2H2O), 2.5 mL glutamine solution, and 50 mg of 
collagenase type IA from Clostridium histolyticum (dissolved immediately before use). 
After perfusion, the liver was dissected, removed from the animal, and dissociated in a 
sterile suspension-buffer. This buffer consisted of 124 mL glucose solution, 20 mL 
Krebs-Henseleit-buffer, 20 mL HEPES-buffer II (60 g/L HEPES; adjusted to pH 7.6), 15 
mL MEM non-essential amino acid solution (100x), 15 mL MEM amino acids (10x) 
solution, 2 mL glutamine solution, 1.6 mL CaCl2 solution (19 g/L CaCl2.2H2O), 0.8 mL 
MgSO4 solution (24.6 g/L MgSO4.7H2O), and 400 mg bovine serum albumin (BSA). 
The obtained suspension was purified by three low-speed centrifugations at 250 g, for 
5 min, at 4 °C. The viability of isolated hepatocytes was always above 85 %, as 
assessed by the trypan blue exclusion method. 
3.1.4. Culture of primary rat hepatocytes 
A suspension of 5 x 105 viable cells/mL in complete culture medium was seeded 
onto the central 60 wells of 96-well plates (5 x 104 cells/well) or onto 6-well plates (1 x 
106 cells/well) pre-coated with collagen. Complete cell culture medium consisted of 
William’s E medium (Sigma-Aldrich, Lisbon, Portugal) supplemented with 10 % FBS, 5 
µg/mL insulin solution from bovine pancreas (Sigma-Aldrich, Lisbon, Portugal), 50 nM 
dexamethasone (Sigma-Aldrich, Lisbon, Portugal), 1 % antibiotic solution (100 U/mL 
penicillin, 100 μL/mL streptomycin), 100 μg/mL gentamicin, and 0.25 μg/mL 
amphotericin B. After seeding, primary rat hepatocytes were incubated overnight at 37 
°C, in an atmosphere of 5 % CO2, to promote cell adhesion. On the next day, the cells 
were exposed to the test drug. 
3.1.5. Drug exposures 
Stock solutions of 3-MMC were extemporaneously prepared in Hank’s balanced 
salt solution (HBSS) and further diluted (at least 13x) in exposure medium (i.e. 
complete cell culture medium without FBS). For the cell viability experiments, isolated 
primary rat hepatocytes were exposed to a large interval of 3-MMC concentrations [0.3 
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μM – 10 mM]; all the other assays performed to elucidate the mechanisms responsible 
for the elicited hepatotoxicity were conducted at four test 3-MMC concentrations: 1 μM, 
10 μM, 100 μM and 500 μM. These concentrations were chosen to allow the 
investigation of the toxicological mechanisms triggered by the drug at different effect 
levels. None of them was able to induce significant mortality (p>0.05), precluding 
interference with results on the endpoints to be evaluation. In addition, the lowest 
concentration (10 μM) is in line with the blood concentration found in a fatal intoxication 
(Adamowicz et al. 2016b). All drug incubations were performed for 24 h, at 37 ºC, in a 
humidified, 5 % CO2 atmosphere. Solvent and negative controls were always carried 
out, parallel to drug incubations. Comparison between solvent (HBSS) and negative 
controls (cells treated with cell culture medium) showed no statistically significant 
differences (p > 0.05).  
3.1.6. Exposure to inhibitors of CYP450 
metabolism 
Stock solutions of the inhibitors metyrapone (CYP2E1), quinidine (CYP2D6), 
ketoconazole (CYP3A4) and 1-aminobenzotriazole (ABT; general CYP450) were 
prepared in dimethyl sulfoxide (DMSO) and further diluted in exposure medium 
(ensuring that the final concentration of DMSO did not exceed 0.05 %). One hour 
before exposing the primary rat hepatocytes to 3-MMC, the cells were incubated with 
500 μM of metyrapone, 10 μM of quinidine, 1 μM of ketoconazole and 1 mM of ABT. 
3.1.7. Cell viability by the MTT reduction assay 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction 
assay was performed in a 96-well plate to evaluate the mortality triggered by 3-MMC in 
primary rat hepatocytes. This assay measures cell viability indirectly through the 
succinate dehydrogenase activity, an indicator of metabolically active mitochondria. 
The protocol used was previously described by Dias da Silva et al. (2014b). With the 
purpose of further analysing the metabolic profile of the drug, after 24 h-incubations of 
3-MMC, the culture medium was aspirated and stored frozen at -80 ºC. Then, 100 μL of 
a fresh solution of 1 mg/mL MTT (prepared in HBSS) was added to the attached cells, 
which were further incubated for 3 h, at 37 ºC. After this, the MTT solution was 
aspirated and the formazan crystals, formed after MTT reduction by mitochondrial 
reductases and retained inside the cells, were dissolved with 100 μL of DMSO. After 15 
min shaking, the absorbance was measured in a multi-well plate reader BioTek 
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Synergy™ HT (BioTek Instruments, Inc.) at 550 nm. As the MTT is a photosensitive 
dye, the entire procedure was done under light protection. The data, obtained in 
triplicates of three independent experiments, were normalised to positive (1 % Triton X-
100) controls and results were graphically presented as percentage of negative 
controls. 
3.1.8. Cell viability by the LDH leakage assay 
Cytoplasmic membrane integrity, evaluated through the lactate dehydrogenase 
(LDH) leakage assay, also offers a feasible indication of cell viability. As LDH is a 
cytoplasmic oxidoreductase, its presence in the extracellular medium is indicative of 
alterations in membrane permeability and consequently in cell integrity. The enzyme 
catalyses the reversible conversion of pyruvate to lactate, in the presence of 
nicotinamide adenine dinucleotide (NADH), which is in turn oxidized into NAD+. At the 
end of the incubation period, 10 μL of cell exposure medium was transferred into a 96-
well plate and added with 200 μL of freshly prepared 0.15 mg/mL β-NADH solution. 
Immediately before the absorbance reading, 25 μL of 2.5 mg/mL sodium pyruvate 
solution were added to start the reaction. Both β-NADH and sodium pyruvate solutions 
were prepared in potassium phosphate buffer (0.05 M KH2PO4, pH 7.4). The kinetics of 
the oxidation of NADH to NAD+ was followed by reading the absorbance at 340 nm, 
every 16 seconds, for 3 minutes, using an automatic plate reader Power Wave XTM 
(BioTek Instruments, Inc.). The data, obtained in six replicates of three independent 
experiments, were normalised to the negative controls and results were graphically 
presented as percentage of positive (1 % Triton X-100) controls. 
3.1.9. Cell viability by the NR inclusion assay 
To provide supplementary cell viability data, we performed the neutral red (NR) 
uptake assay. This assay is based on the ability of viable cells to incorporate and bind 
the weak cationic dye NR, which penetrates into the cells by non-ionic diffusion, 
accumulating in lysosomes by interaction with anionic sites in the lysosomal matrix. At 
the end of the 24 h-incubations, the exposure medium of the primary hepatocytes 
seeded onto 96-well plates was replaced by 50 µg/mL NR solution, prepared in HBSS. 
The cells were incubated at 37 ºC in a humidified, 5 % CO2 atmosphere for 3 h, 
allowing the lysosomes of viable cells to take up the dye. Thereafter, the cells were 
carefully washed twice with 200 μL of HBSS to eliminate extracellular dye, and lysed 
with 100 μL of lysis solution (50 % ethanol : 1 % glacial acid acetic : 49 % water). The 
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absorbance was measured at 540 nm in a multi-well plate reader BioTek Synergy™ HT 
(BioTek Instruments, Inc.). The data, obtained in triplicates of four independent 
experiments, were normalised to positive (1 % Triton X-100) controls and results were 
graphically presented as percentage of negative controls. 
3.1.10. Measurement of intracellular reactive 
oxygen (ROS) and nitrogen (RNS) species 
The production of ROS and RNS was evaluated as reported by Dias da Silva et 
al. (2014a). Primary rat hepatocytes seeded onto 96-well plates were incubated with 10 
μM 2’,7’-dichlorofluorescin diacetate (DCFH-DA), for 30–60 min, at 37 ºC, immediately 
before the hepatocyte drug incubations. As DCFH-DA is a lipophilic sensitive probe, it 
readily penetrates the cells producing by hydrolysis 2’,7’-dichlorodihydrofluorescein 
(DCFH), which is further oxidized by intracellular ROS and RNS to the green 
fluorescent 2’,7’-dichlorofluorescein (DCF). A 4 mM DCFH-DA stock solution was 
prepared in DMSO and stored at -20 ºC in an opaque airtight container. Immediately 
before each experiment, the working concentration was made up in fresh culture 
medium (ensuring that the final concentration of DMSO did not exceed 0.05 %). The 
cells were then rinsed twice with HBSS and incubated, at 37 ºC, with 3-MMC test 
concentrations. A blank (no cells) and a negative control (no test drugs) were also 
included in the plate. After a 24h incubation, fluorescence was measured at 485 nm 
excitation and 530 nm emission, on a fluorescence multi-well plate reader (BioTek 
Synergy™ HT, BioTek Instruments, Inc.). The data, obtained in three independent 
experiments run in triplicate, were normalised to the blanks and results were 
graphically presented as percentage of negative controls. 
3.1.11. Sample preparation for measurement of 
intracellular total glutathione (tGSH), 
oxidised glutathione (GSSG) and 
adenosine triphosphate (ATP) 
After drug exposures, primary rat hepatocytes seeded onto 6-well plates were 
rinsed with HBSS and added of 300 μL 5 % HClO4 (w/v) per well. After 20 min at 4 ºC, 
the cells were scrapped and the obtained suspension was centrifuged at 16,000 g for 
10 min at 4 ºC. The supernatants were collected and kept at -80 ºC until determination 
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of total glutathione (tGSH), oxidised glutathione (GSSG) and adenosine triphosphate 
(ATP). The obtained pellet was suspended in 1 M NaOH and used for protein 
quantification, through the Lowry assay. 
3.1.12. Measurement of intracellular total 
glutathione (tGSH) and oxidized 
glutathione (GSSG) 
Determination of tGSH and GSSG was made through the 5,5′-dithiobis(2-
nitrobenzoic acid) (DTNB)-GSSG reductase-recycling assay, as previously described 
(Dias da Silva et al. 2014a). The recycling assay for tGSH is a sensitive and specific 
enzymatic procedure. Reduced glutathione (redGSH) is oxidized by DTNB to give 
GSSG with stoichiometric formation of 5-thio-2-nitrobenzoic acid (TNB). GSSG is 
reduced to redGSH by the action of the highly specific glutathione reductase (GR) and 
NADPH. Briefly, for tGSH determination, the supernatants of samples, blank, and 
standards were neutralized with 300 μL of 0.76 M KHCO3 (until there was no formation 
of CO2 following vortex mixing). The samples were then centrifuged for 10 min at 
16,000 g (4 °C), and 100 μL of each supernatant were added to a 96-well plate, 
followed by 65 μL of a freshly prepared reagent solution. The reagent solution consists 
of 0.69 mM β-Nicotinamide adenine dinucleotide 2′-phosphate reduced (β-NADPH) and 
4 mM DTNB, prepared in water. Samples were incubated for 15 min at 30 °C. Then, 40 
µL of 10 U/mL GR solution freshly prepared in phosphate buffer (71.5 mM NaH2PO4, 
71.5 mM Na2HPO4, 0.63 mM EDTA, pH 7.5) were added to each well. The formation of 
TNB was followed for 3 min, every 10 seconds, at 405 nm, using a multi-well plate 
reader (Power Wave XTM, BioTek Instruments, Inc.).To determine intracellular GSSG, 
2-vinylpyridine was used to block reduced glutathione (redGSH). Accordingly, previous 
to sample neutralization with KHCO3, 10 μL of 2-vinylpyridine were added per each 200 
μL of supernatant (samples, blank, and standards) and mixed for 1h, on ice. Then, 
GSSG was determined as described for tGSH. 
The amount of redGSH was calculated by subtracting GSSG from the tGSH, i.e. 
redGSH = tGSH–(2xGSSG). The GSSG and redGSH standard solutions were 
prepared in 5 % HClO4; the concentrations ranged between 0.25–8 µM for GSSG and 
between 0.25–15 µM for GSH. Results from three independent experiments were 
normalised to the amount of protein of the sample and presented as nmol per mg of 
protein. 
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3.1.13. Assessment of mitochondrial membrane 
potential (ΔΨM) 
The mitochondrial integrity was determined through the evaluation of 
tetramethylrhodamine ethyl ester (TMRE) inclusion, as described by Dias da Silva et al. 
(2014a). As TMRE is a cell permeable fluorescent dye positively charged, it labels 
active mitochondria by accumulation, a consequence of their relative negative charge. 
A 2 mM TMRE stock solution was initially prepared in DMSO and stored at -20 °C, 
protected from light. Immediately before each experiment, the working concentration 
was made up in fresh culture medium (ensuring that the final concentration of DMSO 
did not exceed 0.05 %). After the 3-MMC incubation period, the exposure medium was 
replaced by fresh medium containing 2 μM TMRE, and primary hepatocytes seeded 
onto 96-well plates were further incubated at 37°C, for 30 min, in the dark. The cells 
were washed twice with HBSS and the fluorescence was quantified on a fluorescence 
multi-well plate reader (BioTek Synergy™ HT, BioTek Instruments, Inc.) set to 544 nm 
excitation and 590 nm emission. Since TMRE is photosensitive, all steps were 
performed under light protection. The data, obtained in triplicates of three independent 
experiments, were normalised to the blanks and results were graphically presented as 
percentage of negative controls.  
3.1.14. Measurement of intracellular adenosine 
triphosphate (ATP) 
Determination of ATP was made through a bioluminescence assay that measures 
the light formed in the oxidation of luciferin, catalysed by luciferase in the presence of ATP, 
as described by Dias da Silva et al. (2014b). After neutralization of the thawed acidic 
supernatants with an equal volume of 0.76M KHCO3, the samples were centrifuged for 10 
min at 16,000 g, at 4 °C. Then, 75 μL of the neutralized supernatants, standards, or blank 
(5 % HClO4, w/v) were transferred in triplicate to 96-well white plates and then added of 75 
μL of the luciferin/luciferase solution. Luciferin/luciferase solution consisted of 0.15 mM 
luciferin, 300,000 light units of luciferase from Photinus pyralis (American firefly), 50 mM 
glycine, 10 mM MgSO4, 1 mM Tris, 0.55 mM EDTA, and 1 % BSA (pH 7.6). Using a 
luminescence multi-well plate reader (BioTek Synergy™ HT, BioTek Instruments, Inc.), the 
emitted light intensity of the samples was evaluated and compared with an ATP standard 
curve (31.25–1000 μM) performed within each experiment. Data from three independent 
experiments were normalized to the protein content, and results were expressed as nmol 
per mg of protein. 
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3.1.15. Determination of protein 
The protein content in the samples for normalisation of ATP and GSH/GSSH 
assays was measured through the method of Lowry et al. (1951). Accordingly, 50 μL of 
each sample, standard, or blank were transferred into a 96-well plate, in triplicate, and 
added of 100 μL reagent A (14.7 mL of 2 % Na2CO3, 0.15 mL of 2 % 
KNaC4H4O6.4H2O, and 0.15 mL of 1 % CuSO4.5H2O, extemporaneously prepared). 
The plate was incubated in the dark for 10 min, at room temperature, followed by the 
addition of 100 μL of reagent B (Folin and Ciocalteu’s phenol reagent, diluted 15x in 
purified water). The plate was incubated for 10 min, under light protection, at room 
temperature, and the absorbance was measured at 750 nm in a 96-well microplate 
reader (Power Wave XTM, BioTek Instruments, Inc.). Protein standards (31.25–500 
μg/mL) were prepared with BSA in 1 M NaOH. 
3.1.16. Determination of caspase-3, caspase-8 and 
caspase-9 
After 24 h-incubations of hepatocytes seeded onto 6-well plates with 3-MMC at 
37 °C, the cell treatment medium was discarded (two wells were used per each 
treatment condition) and added of 75 µL of lysis buffer (50 mM HEPES, 0.1 mM EDTA, 
0.1 % CHAPS, 1 mM DTT, pH 7.4). Following incubation at 4 ºC, for 30 min, cells were 
scrapped and collected into 2 mL centrifuge tubes. After homogenization, samples 
were centrifuged at 16,000 g for 10 min, at 4 °C. Fifty μL of the supernatant 
(cytoplasmic fraction) were transferred into wells of a 96-well plate and then added of 
200 μL of assay buffer (100 mM NaCl, 50 mM HEPES, 1 mM EDTA, 0.1 % CHAPS, 10 
% glycerol, 10 mM DTT, pH 7.4). To start the reaction, 5 µL of caspase-3 (Ac-DEVD-
pNA; 4mM in DMSO), caspase-8 (Ac-IETD-pNA; 10mM in DMSO), or caspase-9 (Ac-
LEHD-pNA; 10mM in DMSO) peptide substrate were added and incubated at 37 °C for 
24 h, protected from light. The caspase-induced release of the p-nitroanilide moiety of 
the substrate was assessed by measuring absorbance at 405 nm, in a multi-well plate 
reader (BioTek Synergy™ HT, BioTek Instruments, Inc.), as previously described 
(Dias-da-Silva et al. 2015). The absorbance of blanks (non-enzymatic control) was 
subtracted from each value of absorbance and the data normalized to the amount of 
protein of each sample. The protein content in the cytoplasmic fraction was quantified 
using the Bio-Rad DC protein assay kit, as described by the manufacturer, and BSA 
solutions were used as standards (31.25 µg/mL – 1 mg/mL). Results from three 
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independent experiments were normalised to the amount of protein in each sample and 
expressed as percentage of negative controls. 
3.1.17. Statistical analysis 
The normalized MTT, LDH, and NR assays data were fitted to the dosimetric 
Logit model, which was chosen based on a statistical goodness-of-fit principle: y = 
θmax/{1 + exp[−θ1 − θ2 * log(x)]}, where θmax is the maximal observed effects, θ1 is the 
parameter for location, θ2 is the slope parameter and x is the concentration of test 
drug. To compare concentration-response curves, overlapping of the 95 % confidence 
intervals was used and, additionally, the extra sum-of-squares F test. The Lowest 
Observed Effect Concentrations (LOECs) and No Observed Effect Concentrations 
(NOECs) were calculated by testing a trend in concentration effects against control by 
applying hypothesis-testing procedures (unpaired t tests) (Silva et al. 2007), which 
allowed the estimation of LOECs. Consequently, the next lower tested concentrations 
could be designated as NOEC values. Results from determination of ROS/RNS, 
GSH/GSSG, Δψm, caspase -3, -8, -9 activities, and ATP were presented as mean ± 
standard error of the mean (SEM) from three independent experiments. Normality of 
the data distribution was assessed by the Kolmogorov–Smirnov, D’Agostino & Pearson 
and Shapiro–Wilk normality tests. Statistical comparisons between groups were 
performed by one-way analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparison test. Solvent and negative control values were compared by the Student’s 
unpaired t test. In all cases, significance was accepted at p values < 0.05. All statistical 
calculations were performed using GraphPad Prism software, version 7.0 (GraphPad 
Software, San Diego, CA, USA). 
3.2. Metabolic profile of 3-MMC by Gas-
Chromatography–Mass Spectrometry (GC–MS) 
3.2.1. Chemicals 
As mentioned before, the hydrochloride salt of 3-MMC was purchased online 
from the Sensearomatic website (http://sensearomatic.net, currently unavailable), in 
March, 2016. Unless stated otherwise, all other chemicals were purchased from 
Sigma-Aldrich (Lisbon, Portugal) and all the cell culture reagents from Gibco® 
(Alfagene, Lisbon, Portugal). Cell culture samples were prepared and used as 
mentioned in sections 1.4–1.7. Methanol (MeOH) and acetonitrile, both HPLC grade, 
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were purchased from Honeywell (Muskegon, USA). Dichloromethane (LC-MS grade), 
ammonium hydroxide (NH4OH, 32 %), potassium dihydrogen phosphate (KH2PO4, 
analytical grade) and sodium acetate trihydrate (C2H3NaO2.3H2O, analytical grade) 
were obtained from Merck Co (Darmstadt, Germany). Hydrochloric acid (HCl) (37 %) 
was obtained from Fisher Scientific (UK). Sodium hydroxide (NaOH) (analytical grade), 
sodium chloride (NaCl) (analytical grade), HCl (analytical grade), 2-propanol (analytical 
grade) and n-hexane (HPLC grade) were purchased from VWR international (Spain). 
All reagents used were of analytical grade. Solid-phase extraction (SPE) was 
performed using Oasis MCX® SPE 1 cm3 (30 mg) columns obtained from Waters 
(Milford, Massachusetts) and the Supelco VisiprepTM SPE Vacuum Manifold from 
Sigma-Aldrich (St. Louis, Missouri). 
3.2.2. Standard solutions and calibrators 
Stock solutions of 3-MMC and internal standards (IS), 4-hydroxy-3-
methoxybenzylamine hydrochloride (IS1) and phenylpropanolamine (IS2), were 
prepared at 1 mg/mL in MeOH and stored at -20ºC. All intermediate dilutions and 
working solutions were also prepared in MeOH. 
Eight methods of extraction were tested. For the extraction methods 1, 3–8 
(Table 7), working calibrators for cell culture medium at 125, 175, 250, 500 and 1000 
ng/mL were prepared by adding 100 μL of each 3-MMC standard to 900 μL of 
exposure medium (see composition in section 1.5). For method 2 (Table 7), working 
calibrators were prepared by diluting a 500 ng/mL 3-MMC stock solution in the volume 
of exposure medium necessary to made up 500 μL; then 1.5 mL of 0.1 M phosphate 
buffer (pH 4.4) was added. 
3.2.3. Biological specimens 
As mentioned above, the culture medium from primary rat hepatocyte exposures 
to 3-MMC was aspirated before performing the MTT assay. These samples were 
stored frozen at -80 ºC until further use for GC-MS analysis. 
3.2.4. Extraction 
Several methods of extraction were tested for further selection of the method 
presenting lower limit of detection, better linearity and extraction efficiency. The 
extraction methods tested are described in Table 7. 
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After extraction, the sample was evaporated to dryness under nitrogen (N2) 
stream, and then added with 50 µL of 500 ng/mL IS1 or IS2 and evaporated again. 
Table 7 Methods of extraction tested.  
Extraction 
method 
Type of 
extraction 
Protocol steps 
1 SPE 
1. Load the sample 
2. Wash with 2 mL of HCl 0.1 M and 2 mL of MeOH 
3. Elute with 2 mL of 5 % NH4OH/MeOH solution 
2 SPE 
1. Condition with 2 mL of MeOH and 2 mL of H2O 
(deionized) 
2. Load the sample 
3. Wash with 2 mL of H2O (deionized), 2 mL of HCl 0.1 M, 
2 mL of dichloromethane:methanol (70:30 v/v)1 and 2 mL 
n-hexane 
4. Elute with 2 mL dichloromethane:2-propanol:NH4OH 
(78:20:2 v/v/v) 
3 
Liquid-
liquid 
1. Adjust sample pH above 11 with 1 M NaOH 
2. Add 1 mL of TBME 
3. Vortex for 30 s, then centrifuge at 5600 g for 5 min 
4. Transfer supernatant into a 4 mL vial 
5. Repeat steps 2–4 twice 
4 
Liquid–
liquid 
followed by 
SPE 
1. After extracting with method 3, evaporate samples till 
dryness 
2. Dissolve the residue in 3 mL of 0.2 M sodium acetate 
buffer (pH 5.2) 
3. Load columns with 3 mL of 0.2 M sodium acetate buffer 
(pH 5.2) 
4. Extraction with method 1 
5 QuEChERS 
1. Add 5 mL of acetonitrile to 1 mL of sample 
2. Add 2 g of MgSO4 anhydrous and 0.5 g of NaCl 
3. Vortex for 30 s. Then, centrifuge at 5600 g for 3 min 
4. Collect supernatant into a 4 mL vial 
6 QuEChERS 
1. Add 5 mL of MeOH to 1 mL of sample 
2. Add 2 g of MgSO4 anhydrous and 0.5 g of NaCl 
3. Vortex for 30 s then centrifuge at 5600 g for 3 min 
4. Transfer supernatant into a 4 mL vial 
7 QuEChERS 
1. Adjust the sample pH to 5 or11 
2. Add 2 mL of ultra-pure H2O and 5 mL of acetonitrile 
3. Add 2 g of MgSO4 anhydrous and 0.5 g of NaCl 
4. Vortex for 30 s. Then, centrifuge at 5600 g for 3 min 
5. Transfer supernatant into a 4 mL vial 
8 QuEChERS 
1. Adjust the sample pH to 5 or 11 
2. Add 3 mL of TBME 
3. Add 750 mg of MgSO4 anhydrous and 100 mg of NaCl 
4. Vortex for 30 s. Then centrifuge at 5600 g for 3 min 
5. Transfer supernatant into a 4 mL vial 
SPE – Solid-phase extraction; HCl - Hydrochloric acid; MeOH – Methanol; NH4OH – Ammonia solution; H2O – Water; 
NaOH – Sodium hydroxide; TBME - Tert-butylmethylether; QuEChERS - Quick, Easy, Cheap, Effective, Rugged, and 
Safe; MgSO4 – Magnesium sulfate; NaCl – Sodium chloride  
The method 2 was adapted from Margalho et al. (2016); the methods 1, 3, and 4 were adapted from Moreira (2015); the 
method 5 adapted from Almada et al. (2016). 
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3.1.1. Derivatization 
Three methods of derivatization were tested, as described in Table 8. The N-
Methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA) derivatization procedure used was 
previously described by Magalhães (2015). The trifluoroacetic anhydride (TFAA)  
derivatization procedure used was previously described by da Silva et al. (2010). The 
heptafluorobutyric anhydride (HFBA) derivatization procedure was adapted from Jamey 
et al. (2016). 
For the methods of extraction 5, 7 and 8, an additional step for the removal of the 
derivatization reagent HFBA was made, as previously described by Petrarca et al. 
(2017). Briefly, before dissolving the residue in ethyl acetate, it was dissolved in 1 mL 
of phosphate buffer solution (pH 7.4) and 3 mL of dichloromethane. After agitating by 
vortex, the dichloromethane phase (bottom layer) was collected, dehydrated with 100 
mg of MgSO4 anhydrous and evaporated to dryness under a stream of N2. Finally, the 
residue was dissolved in 100 μL of ethyl acetate, and 1 μL was submitted to GC-MS 
analysis. 
Table 8 Derivatization procedures tested. 
Derivatization 
reagent 
Derivatization procedure 
MSTFA 
1. Add 60 µL of MSTFA to the dry residue 
2. Vortex for 30 s 
3. Heat at 80 ºC for 30 min 
4. Cool to room temperature 
TFAA 
1. Add 50 µL of ethyl acetate and 50 µL of TFAA to the dry residue 
2. Vortex for 30 s 
3. Heat at 70 ºC for 30 min 
4. Cool to room temperature and evaporate till dryness under N2 
stream 
5. Dissolve the residue in 100 µL of ethyl acetate 
HFBA 
1. Add 50 µL of ethyl acetate and 50 µL of HFBA to the dry residue 
2. Vortex for 30 s 
3. Heat at 60 ºC for 30 min 
4. Cool to room temperature and evaporate till dryness under N2 
stream 
5. Dissolve the residue in 100 µL of ethyl acetate 
MSTFA – N-methyl-n-(trimethylsilyl)trifluoroacetamide; TFAA – Trifluoroacetic anhydride; HFBA – Heptafluorobutyric 
acid 
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3.1.2. Interferences 
In order to evaluate the presence of chromatographic interferences for all tested 
methods, blank medium samples were prepared in parallel and analysed at the 
retention times of 3-MMC and IS. The chromatograms of spiked samples were then 
compared with the chromatograms obtained with the blank medium samples. 
3.1.3. Chromatographic conditions and 
equipment 
The GC-MS analysis was carried out using a HP 6890 series gas chromatograph 
(Agilent, Little Falls, DE, USA) equipped with Agilent 5973 Network MSD (Mass 
selective detector). A capillary column Rxi-5sil (30 m x 0.25 mm x 0.25 μm) from 
RESTEK was employed for the separation. The software used in the control, 
acquisition and data treatment was Agilent MSD Productivity ChemStation for GC and 
GC/SD Chemstation from Agilent Technologies (Santa Clara, CA, USA). Helium C-60 
(Gasin, Portugal), at a constant flow rate of 1 mL/min, was used as the carrier gas. The 
injection of 1 μL of derivatized extracts was manually done in the splitless mode at 270 
ºC. The column oven temperature was maintained at -80 ºC for 1 min, and then raised 
to 290 ºC at 25 ºC/min, and held at 290 ºC for 5.6 min, with a total run of 15 min. This 
method was adapted from Adamowicz et al. (2014) and from Zuba and Adamowicz 
(2016). The transfer line temperature was 280 ºC, and the electron energy was 70 eV. 
During the first 4 min, the ionization was maintained off to avoid solvent overloading. 
Data were collected at m/z 40-500. Mass spectra acquisition was performed between 4 
and 15 min after the injection of the sample. Full scan mode allowed the detection of all 
ions and was used for the characterization of the spectra and identification of 
compounds; selected ion monitoring (SIM) mode allowed quantification of compounds. 
The ions selected for monitoring were chosen based on the specificity and abundance 
on the mass spectrum. 
The identification of each analyte in the samples was made by comparing the 
retention times and the mass spectra (relative abundance of the ions) of the standards 
with those of the peaks obtained when injecting the samples under the same 
chromatographic conditions (see Tables 11 and 12 of section 4.2.3. of Chapter 4 – 
Results and discussion). 
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3.1.4. Quantitative determination of 3-
methylmethcathinone in samples 
3.1.4.1. Limit of detection (LOD) and limit of 
quantification (LOQ) 
In this study, the limit of detection (LOD) and limit of quantitation (LOQ) were 
determined based on the signal-to-noise ratio. A signal-to-noise ratio of 3 and 10 is 
considered acceptable for estimating the LOD and LOQ, respectively. The 125 ng/mL 
working calibrator was progressively diluted (factor of 2) with cell culture medium to 
determine those limits. 
3.1.4.2. Linearity studies 
Working calibrators at 125, 175, 250, 500 and 1000 ng/mL were prepared and 
stored at -20 ºC. Regression curves were obtained by plotting the peak-area ratio 
between each analyte and the IS against analyte concentrations. Linearity was 
evaluated by the coefficient of determination (R2). At least three independent curves 
were obtained. 
3.1.4.3. Extraction efficiency 
The extraction efficiency was tested at three different concentrations of 3-MMC 
(12.5, 25 and 50 ng/mL), performing four replicates for each concentration. One set of 
samples was spiked with the analytes to the elution/supernatant of the samples before 
evaporation to dryness (non-extracted samples). To the other set of samples, the 
analytes were added before extraction (extracted samples). In both set of samples the 
IS (IS1 or IS2) was added after evaporation to dryness followed by evaporation to 
dryness again. Extraction recovery (%) was calculated comparing the peak area ratios 
of analyte to IS for extracted and non-extracted samples [Extraction recovery (%) = 
mean peak area ratio of extracted samples / mean peak area ratio of non-extracted 
samples) x 100]. 
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4.1. Cytotoxic profile of 3-MMC 
4.1.1. Lysosome was the most sensitive 
organelle to 3-methylmethcathinone (3-
MMC)–induced toxicity, followed by 
mitochondria and by the cytoplasmic 
membrane 
Cellular viability was evaluated by three different assays (LDH, NR, and MTT 
assay) after the exposure of primary rat hepatocytes to a range of 3-MMC 
concentrations that enabled obtaining complete cytotoxic profiles (concentration-
dependent responses from 0 % to 100 % of mortality). The comparison of the obtained 
results provided information about the relative sensitivity of the target organelles, when 
the cell was exposed to 3-MMC. As shown in Fig. 3, 3-MMC-induced toxicity was 
perceived in the lysosome at lower concentrations (NR LOEC 379.5 µM) than those 
needed to cause damage to mitochondria (MTT LOEC 531.2 µM) and cytoplasmic 
membrane (LDH LOEC 1.32 mM). Accordingly, also the potency of 3-MMC for 
provoking cell death was distinct among the different assays (Table 10; NR EC50) 1.36 
mM; MTT EC50 1.68 mM; LDH EC50 3.13 mM). 
Fig. 3 Cell death after 24 h-exposures at 37 ºC of primary rat hepatocytes to 3-methylmethcathinone (3-MMC), 
obtained in the lactate dehydrogenase leakage assay (LDH, data displayed in yellow), neutral red uptake assay 
(NR, data displayed in red), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium reduction assay (MTT, data 
displayed in purple), as indirect measures of cell viability. Data are presented as percentage of cell death relative to 
the negative controls and are from at least three independent experiments performed in triplicate. Curves were fitted to 
the dosimetric Logit model (parameters displayed in Table 10). The dotted lines are the upper and lower limits of the 95 
% confidence interval of the best estimate of mean responses. Differences between the best fits were deemed 
statistically significant, as their corresponding 95 % confidence belts did not overlap. The dashed grey lines represent 
50 % and 100 % effect. 
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By comparison with data available in the literature, 3-MMC is generally less 
damaging to the mitochondria than most cathinones and other substituted 
amphetamines, as shown in Table 9. The exceptions detected were 4-
fluoromethcathinone (4-FMC or flephedrone; EC50 2.21 mM) and 6-(2-
aminopropyl)benzofuran (6-APB; EC50 1.94 mM) that revealed slightly lower  
cytotoxicities in primary rat hepatocytes (Bravo 2016). In spite of the apparent closely 
related chemical structure, the toxicities of 3,4-dimethylmethcathinone (3,4-DMMC; 
EC50 160 μM) and 4-MEC (EC50 840 μM) were significantly much higher than that for 3-
MMC (EC50 1.68 mM) (Bravo 2016; Valente et al. 2016). This is in accordance with 
reports of users that refer the effect of 3-MMC as less potent and intense than 4-MMC 
(Adamowicz et al. 2016a; Sande 2016).  
Also, the damage caused by 3-MMC to the cytoplasmic membrane was lower 
than that provoked by methylenedioxypyrovalerone (MDPV; EC50 2.06 mM) and MDMA 
(EC50 1.99 mM) but slightly higher than that for methylone (EC50 3.20 mM). 
Nevertheless, these differences might be justified by the fact of using of different cell 
models (MDPV, MDMA and methylone were tested in dopaminergic SH-SY5Y neuron-
like cells). In regard of the damage to the lysosome, no data was found in the literature 
for comparison. 
Table 9 Estimated EC50 values (mM) for each compound in three different cytotoxic assays: lactate 
dehydrogenase leakage assay (LDH), neutral red uptake assay (NR), and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium reduction assay (MTT). The MTT EC50 values are estimated in primary rat hepatocytes and the 
LDH EC50 values are estimated in dopaminergic SH-SY5Y neuron-like cells. Adapted from Bravo (2016), Valente et al. 
(2016) and Valente et al. (2017b). 
Drug Class Drug MTT LDH NR 
Substituted 
Cathinone 
Butylone 1.21   
Buphedrone 1.57   
3,4-DMMC 0.16   
4-FMC 2.21   
MDPV 0.76 2.06  
Pentedrone 0.66   
4-MEC 0.84   
Methylone 1.26 3.20  
Other 
amphetamine-
related drugs 
6-APB 1.94   
5-APB 0.96   
MDMA 1.07 1.99  
3-MMC – 3-methylmethcathinone; 3,4-DMMC – 3,4-dimethylmethcathinone; 4-FMC – 4-fluoromethcathinone; MDPV – 
methylenedioxypyrovalerone; 4-MEC – 4-methylethcathinone; 6-APB – 6-(2-aminopropyl)benzofuran; 5-APB – 5-(2-
aminopropyl)benzofuran; MDMA – 3,4-Methylenedioxymethamphetamine 
Results for 3-MMC obtained in the current study were 1.68 mM in the MTT assay, 3.13 mM in the LDH assay and 1.36 
mM in the NR assay, after 24 h of exposure in primary rat hepatocytes. 
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4.1.2. Cytochrome P450 (CYP450) metabolism 
impacts hepatotoxicity elicited by 3-
methylmethcathinone (3-MMC) 
To estimate the role of metabolism through the main CYP450 enzymes in the 
hepatotoxicity caused by 3-MMC, primary rat hepatocytes were treated with specific 
inhibitors of its different isoforms, namely CYP2D6, CYP2E1 and CYP3A4; a general 
inhibitor of CYP450 was additionally used. Results are represented in Fig. 4 and Table 10. 
Fig. 4 Cell death obtained in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) reduction assay, as 
an indirect measure of cell viability, after 24 h-exposures at 37 ºC of primary rat hepatocytes to 3-
methylmethcathinone (3-MMC), in the presence (coloured solid lines) or absence (black solid line) of different 
inhibitors of cytochrome P450 isoforms (CYP). Data are presented as percentage of cell death relative to the 
negative controls and are from three independent experiments performed in triplicate. Curves were fitted to the 
dosimetric Logit model (parameters displayed in Table 10). The dashed grey lines represent 50 % and 100 % effect. 
Metyrapone was used as specific inhibitor of  the isoform CYP2E1 (purple solid line); quinidine was used as specific 
inhibitor of the isoform CYP2D6 (green solid line); ketoconazole was used as specific inhibitor of the isoform CYP3A4 
(orange solid line); and 1-aminobenzotriazole (ABT) was used as general inhibitor of cytochrome P450 (blue solid line). 
Each inhibitor concentration was selected in order to induce inhibition without 
eliciting cytotoxicity, as already optimized for our experimental settings (cellular model 
and viability assay) by Dias-da-Silva et al. (2015). When treated with metyrapone 
(CYP2E1 inhibitor), the concentration-response curve (EC50 1.40 mM) was shifted to 
the right, at the lower 3-MMC concentration range, indicating lower toxicity, compared 
with the control. This suggests that metabolism of 3-MMC through CYP2E1 is 
hepatotoxic at concentrations up to ~ 1.20 mM, which could indicate either a 
bioactivation of 3-MMC through this enzyme or the drug entering in an alternative 
metabolic pathway that results in higher toxicity. For the latter case, we further 
hypothesised the saturation of the enzymes involved in this substitute route, since an 
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inversion of the cytotoxic profile was observed (the inhibition of CYP2E1 increased cell 
death) at concentrations higher than ~ 1.20 mM. 
Table 10 Estimated parameters for the Logit model (best-fit regression) of 3-methylmethcathinone (3-MMC) in 
the different viability assays, after 24 h-incubation at 37 ºC of primary rat hepatocytes, in the presence or 
absence of different isoforms of cytochrome P450 (CYP) inhibitors.  
Assay 
CYP 
inhibitor 
Parameters for the 
Logit regression 
model 
EC50
 
(mM) 
NOEC 
(mM) 
LOEC 
(mM) 
p value 
θ1
a θ2
b θmax
c 
MTT 
No inhibitor -1.65 7.14 101.40 1.68 0.38 0.53 - 
CYP 3A4 -1.69 6.93 103.70 1.71 0.53 0.64 
p = 0.9758 (vs. no 
inhibitor) 
CYP 2E1 -2.36 16.70 96.08 1.40 0.74 1.04 
p = 0.0031 (vs. no 
inhibitor) 
CYP 2D6 -3.19 10.15 97.96 2.08 1.04 1.25 
p = 0.0005 (vs. no 
inhibitor) 
CYP 450 -1.68 10.00 101.30 1.46 0.74 1.04 
p = 0.0288 (vs. no 
inhibitor) 
LDH No inhibitor -4.44 8.96 100.20 3.13 1.04 1.31 
p < 0.0001 (vs. 
MTT no inhibitor) 
NR No inhibitor -0.93 6.62 102.30 1.36 0.31 0.38 
p = 0.0061 (vs. 
MTT no inhibitor) 
Metyrapone at 500 μM was used as specific inhibitor of the isoform CYP2E1; quinidine at 10 μM was used as specific 
inhibitor of the isoform CYP2D6; ketoconazole at 1 μM was used as specific inhibitor of the isoform CYP3A4; and 1-
aminobenzotriazole (ABT) at 1 mM was used as general inhibitor of CYP450. LDH, lactate dehydrogenase leakage. NR, 
neutral red uptake. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium reduction. NOEC, no observed effect 
concentration. EC50, concentration of 3-MMC that gives half-maximal response, i.e. 50 % effect, in the respective assay. 
aLocation parameter. bSlope parameter. cMaximal effect, expressed as % cell death (data scaled between 0 and 100 % 
cell death, corresponding to negative controls and positive controls, respectively). Comparisons between curves (θmax, 
θ1 and θ2) were performed using the extra sum-of-squares F-test. p values lower than 0.05 were considered statistically 
significant. 
On the other hand, when CYP2D6 was inhibited by quinidine (EC50 2.08 mM), 
higher 3-MMC concentrations were needed to induce similar levels of cell death, 
compared to the control (EC50 1.68 mM). This suggests that CYP2D6 might be 
responsible for the bioactivation of the drug, as this also occurs for other amphetamine 
derivatives. Accordingly, it is known that MDMA undergoes CYP2D6-mediated 
bioactivation with formation of catechols, which are highly reactive molecules that enter 
in redox cycles, Moreover, in vitro studies suggest that 4-MMC is mainly metabolized 
through CYP2D6 and therefore co-administration with other substances might alter 
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toxicity of the drug (Pedersen et al. 2013). Since the drug is an isomer of 4-MMC, one 
could speculate that the metabolization of both cathinones is similar. Although our 
findings contradict this assumption and more likely support bioactivation of 3-MMC 
through this CYP450 isoform. 
Inhibition of CYP3A4 with ketoconazole produced results undistinguishable from 
the control. This isoform has a major role in the detoxification of several drugs (Zanger 
and Schwab 2013) and its function is highly redundant. Accordingly, when CYP3A4 is 
inhibited, for example by competition with other substances, the drugs such as 3-MMC 
undergo biotransformation through other metabolic pathways. Overall, it seems that 3-
MMC metabolism through CYP450 is detoxifying at biologically relevant 
concentrations, as CYP450 general inhibition with ABT only increased cell death from 
~ 1.03 mM on (EC50 1.71 mM). 
To the best of our knowledge, there is no further information regarding 3-MMC 
metabolism. 
4.1.3. 3-Methylmethcathinone (3-MMC) 
increases intracellular reactive oxygen 
(ROS) and nitrogen (RNS) species 
An increase in the production of reactive species (ROS and RNS) can be due to 
several physiological processes that occur in the cell, the most preponderant of them 
consists on the activity of the mitochondrial electron transport chain. Since the cell has 
defence mechanisms against production of reactive species, oxidative stress will only 
occur when there is an imbalance between the prooxidants and the antioxidants (in 
favour of the oxidants). Accordingly, a rise in the ROS/RNS burden causes the 
decrease of antioxidant protection and will ultimately result in failure to repair oxidative 
damage. As represented in Fig. 5, ROS and RNS production following exposure to 3-
MMC increased with the increasing concentrations of the drug. Although at 1 µM, 3-
MMC already induced an increase in ROS/RNS levels by 25 %, this augment only 
presented statistical significance (p < 0.05) when 3-MMC was present at higher 
concentrations (≥ 10 µM). 
The formation of ROS and RNS is one of the mechanisms responsible for the 
toxicity of amphetamines, in primary rat hepatocytes (Dias da Silva et al. 2014a) and it 
was also reported for other cathinones, but at higher concentrations (Valente et al. 
2016). Valente et al. (2016) showed that 4-MEC induced a significant increase in this 
stress parameter from 400 µM on. Similar levels of disturbance in production ROS and 
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RNS also occurred for 3,4-DMMC, 4-FMC and MDMA at concentrations as higher as 
142 µM, 1.7 mM, and 1 mM, respectively (Bravo 2016; Dias da Silva et al. 2014a). 
Fig. 5 Production of reactive species of oxygen (ROS) and nitrogen (RNS), measured through the 2′,7′ -
dichlorofluorescin diacetate (DCFH-DA) assay, in rat primary hepatocytes after 24-h incubation with 3-
methylmethcathinone (3-MMC), at 37 °C. Results are expressed as percentage control ± standard error of the mean 
(SEM) from three independent experiments, run in triplicate. Statistical comparisons were made using one-way 
ANOVA/Dunnett’s post hoc test. *p < 0.05; ****p < 0.0001, versus control. 
4.1.4. Intracellular levels of reduced (redGSH) 
and oxidized glutathione (GSSG) are 
affected by 3-methylmethcathinone (3-
MMC) 
Glutathione is an important antioxidant that prevents cell damage induced by 
ROS/RNS. Therefore, the evaluation of redGSH and GSSG levels in primary rat 
hepatocytes exposed to 3-MMC was used to provide complementary information on 
the redox cell status. 
As depicted in Fig. 6, the increase in the ROS and RNS production is consistent 
with the redGSH depletion observed herein. Accordingly, the results from our study 
indicate that a significant decline in redGSH was observed for all concentrations of 3-
MMC tested (p < 0.01, ANOVA/Dunnett’s), with the exception of 10 µM. This might 
mean that, at this concentration, the cell is trying to respond to the insult triggered by 
the drug by activating pro-survival mechanisms. At the two highest concentrations (100 
µM and 500 µM), however, the capacity of cell response was exceeded and a decline 
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in the redGSH, which is consistent with the reduction of the redGSH/GSSG ratio and 
the increase in the production on ROS and RNS, was observed. 
Despite a slight 3-MMC-induced increase in the intracellular levels of GSSG, 
compared to control incubations (4.59 ± 0.26 nmol GSSG/mg protein), there were no 
significant alterations on this parameter, except when the drug was tested at the 
highest concentration. Accordingly, when 3-MMC was incubated at 500 µM, it induced 
an increase in GSSG to 8.24 ± 1.93 nmol GSSG/mg protein (Fig. 6, p < 0.05, 
ANOVA/Dunnett’s). Cells exposed to high levels of oxidative stress, accumulate GSSG 
with reduction of the redGSH/GSSG ratio, an evidence of oxidative stress. Accordingly, 
our data also show a significant decrease of redGSH/GSSG ratio after all cell 
treatments (Fig. 6, p < 0.0001, ANOVA/Dunnett’s). 
Some compounds, such as MDMA, methylone and MDPV, can suffer extensive 
hepatic metabolism into catechols and be further oxidized to very unstable 
orthoquinones (Pedersen et al. 2013; Strano-Rossi et al. 2010; Valente et al. 2017b). 
These molecules can enter into redox chain reactions, inducing massive formation of 
ROS. When glutathione is conjugated with these orthoquinones, it produces 
glutathione-S-yl-adducts, which are still redox active and thus can be readily oxidized 
and further reduced by a second molecule of glutathione, resulting in 2,5-bis-
(glutathione-S-yl)-conjugates. Formation of such conjugates might justify the 
discrepancies observed regarding the decrease of redGSH which was not 
compensated by the GSSG increase. The cell extrusion of the GSSG formed is also a 
possible explanation for this observation. 
Fig. 6 Intracellular contents of reduced (redGSH) and oxidized glutathione (GSSG), and intracellular 
redGSH/GSSG ratio in rat primary hepatocytes after 24 h-incubation with 3-methylmethcathinone (3-MMC). 
Results are expressed as mean ± standard error from the mean (SEM) from four independent experiments. Statistical 
comparisons were made using one-way ANOVA/Dunnett’s post hoc test. *p < 0.05; ***p < 0.001; ****p < 0.0001, versus 
control. 
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4.1.5.  3-Methylmethcathinone (3-MMC) does 
not alter mitochondrial membrane 
potential 
The mitochondria are involved in apoptosis through the propagation of death 
signals originated from the inside (intrinsic apoptotic pathway) or the outside (extrinsic 
apoptotic pathways) of the cell. A significant loss in the mitochondrial inner membrane 
potential impairs oxidative phosphorylation, which causes decrease in energy and 
promotes the release of apoptotic factors (such as caspases), leading to death (Dias 
da Silva et al. 2013). 
The mitochondrial integrity was determined by the evaluation of TMRE inclusion, 
as described by Dias da Silva et al. (2014a). As shown in Fig. 7, although TMRE 
inclusion slightly decreased when primary hepatocytes were exposed to all 
concentrations tested of 3-MMC, this alteration was not statistically significant, 
compared to control. These results were in line with the absence of depolarization of 
the inner mitochondrial membrane for low concentrations of several amphetamine 
derivatives. Accordingly, mitochondrial potential disruption was only observed at 
concentrations higher than 1.8 mM for MDMA, 900 µM for 4-MTA (4-
methylthioamphetamine), and 2.2 mM for d-amphetamine, in HepG2 immortalised 
hepatocytes. For methamphetamine, no effect was observed in the referred study (the 
drug was tested up to 3 mM) (Dias da Silva et al. 2014a). 
Fig. 7 Mitochondrial membrane potential (ΔΨm) measured as TMRE incorporation in mitochondria of rat 
primary hepatocytes after 24-h incubations with 3-methylmethcathinone (3-MMC), at 37 °C. Results are 
expressed as percentage control ± standard error of the mean (SEM) from three independent experiments, run in 
triplicates. No statistical significant differences to control were observed (one-way ANOVA/Dunnett’s post hoc test). 
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4.1.6. Intracellular energetic status of 
hepatocytes was compromised by 3-
methylmethcathinone (3-MMC) at high 
drug concentrations (≥ 100 µM) 
 Maintenance of mitochondrial membrane potential is tightly related to several 
mitochondrial processes, including ATP synthesis. In fact, the mitochondria are the 
main source of ATP, which is used by cells to execute energy-requiring processes. 
This means that ATP generated in the mitochondria is essential to maintain the 
integrity of the cell. 
When cells were treated with 1 µM of 3-MMC, ATP was slightly higher (12.23 %) 
than the control (Fig. 8), supporting the energy-dependent pro-survival mechanisms 
mentioned above. At higher concentrations (≥ 10 µM) cell energetic stores decreased; 
this alteration was statistically significant from 100 µM on (Fig. 8, p < 0.05, 
ANOVA/Dunnett’s). This is in accordance with the significant depletion of redGSH and 
the significant increase in the formation of ROS and RNS. 
Fig. 8 Intracellular ATP levels in primary rat hepatocytes after 24 h-incubation with 3-methylmethcathinone (3-
MMC), at 37 °C. Results are expressed as mean ± standard error of the mean (SEM) from four independent 
experiments. Statistical comparisons were made using one-way ANOVA/Dunnett’s. *p < 0.05; **p < 0.01, versus control. 
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4.1.7. 3-Methylmethcathinone (3-MMC) at 10 µM 
activates pro-apoptotic caspase-3, -8, 
and -9 
As a response to the oxidative injury, the mitochondria undergo extensive 
changes, such as the permeabilization of the mitochondrial membrane with consequent 
release of pro-apoptotic proteins, as cytochrome c. Once in the cytosol, cytochrome c 
triggers a complex signalling cascade, characteristic of the intrinsic mechanisms of 
apoptosis, with the activation of caspase-9 and, subsequently, the executioner 
caspase-3. This leads to the cleavage of intracellular substrates, causing 
morphological and biochemical changes that culminate in cell death. The activation of 
apoptosis also occurs through the extrinsic pathway. The binding of xenobiotics to 
death receptors located in the surface of cell membrane activates this mitochondria-
independent pathway, with subsequent activation of caspase-8, and further direct 
activation of the executioner caspases (such as caspase-3) or indirect activation of the 
intrinsic apoptotic pathway (McIlwain et al. 2013). 
The caspase-3, -8 and -9 activities were evaluated and the results are presented 
in Fig. 9. The activity of the three caspases was maximal when cells were treated with 
10 µM of 3-MMC. At this concentration level, capase-3 activity almost duplicated (189.2 
± 21.9 %), while caspase-8 (148.1 ± 13.8 %) and caspase-9 (155.3 ± 13.5 %) activities 
were approximately 50 % higher than the activity in controls. At higher concentrations 
(100 µM and 500 µM) caspase activities suffered a drastic decrease to levels close to 
controls. This decrease is consistent with the observed reduction of ATP and suggests 
that the hepatotoxicity observed at these concentration levels must follow other forms 
of cell death, such as necrosis, as described before for amphetamines in HepG2 cells 
(Dias da Silva et al. 2013). Further investigation is required to support these 
assumptions and ascertain the pathways involved. The concentration of 3-MMC 
needed to provoke significant alteration in caspases activation in the current study (10 
µM) was much lower than that observed for 4-MEC (1.6 mM) in the same cell model 
(Valente et al. 2016). 
The regulation of the intrinsic pathway of apoptosis is made by pro-apoptotic and 
pro-survival (antiapoptotic) regulators belonging to the BCL-2 family of proteins. The 
pro-apoptotic BCL-2 factors are also implicated in the enhancement of the extrinsic 
death receptor pathway. Some proteins from this family are responsible, for instance, 
for the permeabilization of the outer membrane of the mitochondria. Dias da Silva and 
collaborators (2013) realised a thorough investigation on the apoptotic mechanisms 
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underlying toxicity of four amphetamine derivatives (MDMA, METH, 4-MTA and d-
amph) and showed a decline in antiapoptotic BCL-2 and BCL-XL mRNA levels, with 
concurrent upregulation of the proapoptotic BAX, BIM, BAD (only for MDMA), PUMA 
and BID genes. Elevation of Bax, cleaved Bid, Puma, Bak and Bim (EL, S and L 
isoforms) proteins were further confirmed. According to our observations, additional 
results from the authors showed time-dependent caspase-3/-7 activation, but not ΔΨM 
disruption, mediated amphetamine-induced apoptosis, in HepG2 cells after 24 h 
exposures. The authors also confirmed cell dismantling by poly (ADP-ribose) 
polymerase (PARP) proteolysis. Given the structure and chemical similarity, it is 
possible that comparable mechanisms could be activated for 3-MMC but this 
hypothesis awaits experimental confirmation.  
Fig. 9 Caspase-3, -8, and -9 activities in primary rat hepatocytes after 24-h incubations with 3-
methylmethcathinone (3-MMC), at 37 °C. Results are expressed as percentage of control ± standard error of the 
mean (SEM) from three independent experiments. Statistical comparisons were made using Kruskal–Wallis one-way 
analysis of variance/Dunnett’s post hoc test. *p < 0.05; **p < 0.01; ****p < 0.0001, versus control. 
4.2. Quantification of 3-methylmethcathinone (3-
MMC) by Gas Chromatography–Mass 
Spectrometry (GC–MS) 
4.2.1. Extraction and evaluation of 
interferences 
As mentioned above, studies on 3-MMC are scarce and most information derives 
from case reports. Herein, we proposed to evaluate the impact of 3-MMC metabolism 
on the cytotoxicity elicited by the drug. This type of investigation requires a very robust 
method with high sensitivity and wide linearity ranges for the quantification of the drug 
and its main metabolites in biological samples. So, the first part of this work consisted 
on the optimization of a GC-MS methodology suitable to address these issues. We 
tested several extraction methods and the addition of two different IS until we achieved 
adequate LOD and LOQ, linearity, and extraction efficiency.  
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The first method was adapted from that used for quantifying MDMA and 
piperazines in our laboratory (da Silva et al. 2010; Moreira 2015). In this method, we 
tested the derivatization with TFAA and IS1. Nevertheless, the peak of 3-MMC 
overlapped with IS1, as seen in Fig. 10. We therefore tested the same extraction 
method IS2, but the extraction efficiency for this IS was below 80 %. 
The method 2 was adapted from Margalho et al. (2016), who used it for 
cathinones. Derivatizing the extracts with TFAA produced recovery values that were 
above the acceptable criteria of 100 ± 20 % for this parameter. When these extracts 
were derivatized with HFBA, linearity was poor (R2 = 0.9765) and also variability 
among replicates was noted. This method was deemed unfit for our quantification. 
The methods 3 and 4 had been previously used for extracting piperazines in cell 
culture medium (Moreira 2015). We tested both methods simultaneously with addition 
of IS1 and derivatization with HFBA. When comparing the chromatograms obtained 
from both methods, there were almost no differences (Fig. 11) but the extraction 
efficiency of method 4 was below 80 %. The method 3 showed good reproducibility 
(coefficient of variation, CV, below 5 %) and good linearity in both extracted (R2 = 
0.9887) and non-extracted (R2 = 0.9998). However, the extraction efficiency was 
extremely low for the smallest concentration (~ 50 %) and, at the other concentrations, 
again variability between replicates was noted. Therefore, these methods also had to 
be discarded. 
Fig. 10 Chromatogram obtained by using method of extraction 1, with 4-hydroxy-3-methoxybenzylamine 
hydrochloride (IS1), and derivatization with trifluoroacetic anhydride (TFAA). Ion 119 corresponds to 3-MMC peak 
and ion 345 corresponds to IS1. We can clearly see an overlap of the ions of 3-MMC and IS1. 
We then tested methods 5 and 6 simultaneously. Method 6 was rejected because 
during the evaporation until dryness under N2 flow, many residues were retained in the 
vial and derivatization was not possible due to the sample turbidity. Method 5 was 
tested using IS1 and HFBA as the derivatizing agent. The extraction efficiency was 
below 80 %. Removing the excess of derivatizing reagent before re-injecting the 
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sample did not improve the quality of the chromatograms (Fig. 12) and the method was 
discarded.  
Then, we tested methods 7 and 8 with HFBA derivatization and IS1 with the 
additional step of the removal of the derivatization reagent. For both methods, we 
adjusted the sample either to pH < 5 or pH > 11 aiming to obtain, by comparison, a 
decision on which one produced a better response (higher peak). However, all samples 
tested had an interference at the time of retention of 3-MMC (Fig. 13). We then decided 
to test only method 8 with the pH adjusted to < 5 or > 11, and without the removal of 
the derivatizing reagent, to see if the interference still occurred. However, this did not 
solve the problem, because the interference persisted (Fig. 14). Then we decided to 
test method 8 again with IS2 and without removing the excess of derivatization reagent. 
This last method was chosen to analyse the samples because it showed good 
LOD and LOQ, linearity and extraction efficiency as described below. 
Fig. 11 Chromatograms obtained when extraction was performed with method 3 (1) and 4 (2) with 4-hydroxy-3-
methoxybenzylamine hydrochloride (IS1), and derivatization with heptafluorobutyric acid (HFBA). Ions 119, 373, 
and 254 correspond to 3-MMC peak (α) and ions 545, and 333 correspond to IS1 (β). 
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Fig. 12 Overlaid total ion chromatograms of method 5, with (green) and without (black) removal of excess of the 
derivatization reagent. 
Fig. 13 Chromatograms obtained from injection of an extracted blank sample with method 7 and 8 with 4-
hydroxy-3-methoxybenzylamine hydrochloride (IS1), derivatization with heptafluorobutyric acid (HFBA), and 
removal of the excess derivatizing reagent. Interference peak (α) and IS1 peak (β). (1) Method 7 with pH < 5; (2) 
Method 7 with pH > 11; (3) Method 8 with pH < 5; (4) Method 8 with pH > 11. 
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Fig. 14 Chromatogram obtained from injection of an extracted blank sample with method 8, with 4-hydroxy-3-
methoxybenzylamine hydrochloride (IS1), and derivatization with heptafluorobutyric acid (HFBA). Interference 
peak (α) and IS1 peak (β). 
4.2.2. Derivatization 
When performing a GC analysis, the compounds of interest need to be volatile 
and stable at the high temperatures required for the analysis. However, some 
compounds are not directly suitable to GC analysis due to its poor volatility and/or 
thermal instability. In these cases, chemical derivatization is necessary. Derivatization 
can also be performed to enhance the chromatographic efficiency (peak resolution and 
separation) or even increase detectability. According to the literature, derivatization of 
3-MMC with HFBA (Jamey et al. 2016) and acetic anhydride (Bottinelli et al. 2017) had 
been used previously. Based on this and on the reagent availability at the laboratory, 
we decided to test three different derivatization reagents (MSTFA, TFAA and HFBA). 
Derivatization with TFAA and HFBA consists on an acylation reaction and with MSTFA 
on a silylation. The general mechanism of the three derivatization procedures are 
illustrated in Fig. 15. 
Contrary to derivatization with MSTFA, derivatization with TFAA and HFBA 
produced satisfactory results. However, derivatization with HFBA allowed detection of 
lower concentrations, compared to derivatization with TFAA. For these reasons, the 
chosen derivatizing reagent was HFBA. The proposed fragmentation pattern of both IS1 
and IS2, and 3-MMC are presented in Fig.16. 
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Fig. 15 General mechanisms for derivatization with – N-methyl-n-(trimethylsilyl)trifluoroacetamide (MSTFA) (1), 
trifluoroacetic anhydride (TFAA) (2,3) and heptafluorobutyric acid (HFBA) (4,5).  
 
56 
 
Fig. 16 EI mass spectra of 3-methylmethcathinone (3-MMC) (1), 4-hydroxy-3-methoxybenzylamine hydrochloride 
(IS1) (2) and phenylpropanolamine (IS2) (3) and proposed fragmentation pattern after derivatization with 
heptafluorobutyric acid (HFBA). 
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4.2.3. Chromatographic conditions and 
equipment 
The GC-MS method was adapted from Adamowicz et al. (2014) and from Zuba 
and Adamowicz (2016). The analysis performed with the method described above 
(section 3.2.7. Chromatographic conditions and equipment of Chapter 3 – Materials 
and methods), resulted in good chromatograms with good resolution, the absence of 
co-eluted peaks and an adequate time of analysis. The selected ions for monitorization 
are presented in Table 11. The observed retention times are presented in Table 12. 
Table 11 Selected ions for monitoring. 
Compound 
TFAA ions HFBA ion 
Quantification Identification Quantification Identification 
3-MMC 119 273, 154, 120 119 373, 254, 210 
IS1 345 248, 232 545 348,333 
IS2 140 230, 203, 117 240 330,275 
3-MMC – 3-methylmethcathinone; IS1 – 4-hydroxy-3-methoxybenzylamine hydrochloride; IS2 – phenylpropanolamine; 
TFAA – trifluoroacetic anhydride: HFBA – heptafluorobutyric acid 
Table 12 Retention times for 3-methylmethcathinone (3-MMC) and internal standards (IS). 
Compound 
Retention time (minutes) 
TFAA HFBA 
3-MMC 7.18 6.70 
IS1 7.19 6.87 
IS2 5.24 5.55 
3-MMC – 3-methylmethcathinone; IS1 – 4-hydroxy-3-methoxybenzylamine hydrochloride; IS2 – phenylpropanolamine; 
TFAA – trifluoroacetic anhydride: HFBA – heptafluorobutyric acid 
4.2.4. Quantitative determination of 3-
methylmethcathinone (3-MMC) in 
samples 
After choosing the method 8 for the extraction, the IS2, and the derivatizing 
reagent (HFBA), we performed some additional tests to estimate the LOD and LOQ, 
the linearity, and the recovery. Then, we analysed the samples, i.e. the supernatants 
collected from exposures of primary hepatocytes to several 3-MMC concentrations, 
during the cytotoxicity experiments. 
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4.2.4.1. Limit of detection (LOD) and limit of 
quantitation (LOQ) 
The limit of detection (LOD) and limit of quantitation (LOQ) were determined 
based on the signal-to-noise ratio. To establish the LOD and LOQ, the 125 ng/mL 
working calibrator was progressively diluted (factor of 2) with cell culture medium. The 
LOD was 3.5 ng/mL and the LOQ was 7 ng/mL. 
4.2.4.2. Linearity studies 
The calibration curves obtained showed good linearity (R2 = 0.9980 and R2 = 
0.9975) in the concentration range tested (12.5 – 100 ng/mL) (Fig. 17). 
Fig. 17 Representative calibration curve for 3-methylmethcathinone (3-MMC). 
4.2.4.3. Extraction efficiency 
The extraction efficiencies [Extraction efficiency (%) = (mean peak area ratio of 
extracted samples / mean peak area ratio of non-extracted samples) x 100] were 
determined at three different levels of concentration. The results are presented in Table 
13, and showed recovery values that were at the acceptable criteria of 100 ± 20 % for 
this parameter. 
Table 13 Extraction efficiencies (%) for the method of extraction 8 (n = 2). 
Concentration 
(ng/mL) 
Extraction 
efficiency (%) 
12.5 85 
25 94 
50 96 
y = 0,0097x + 0,0061
R² = 0,9995
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4.2.4.4. Quantification of 3-
methylmethcathinone (3-MMC) in 
samples selected from the 
cytotoxicity experiments 
 Based on the complete cell death profiles obtained in the cytotoxicity 
experiments for 3-MMC (individually or co-incubated with metabolism inhibitors; Fig. 
18), we chose the samples from primary hepatocyte incubations at 0.8 mM, 1 mM and 
1.6 mM of 3-MMC. At these concentrations, the cytotoxicity profiles of 3-MMC, with or 
without CYP450 inhibition, showed significant differences and, therefore, it would be 
interesting to understand whether these differences were accompanied by a different 
extension in the metabolism of 3-MMC. 
Fig. 18 Cytotoxic profiles of 3-methylmethcathinone (3-MMC) following inhibition of CYP2D6 (yellow), CYP3A4 
(red), CYP2E1 (blue) and CYP450 (green), in comparison with no metabolic inhibition (black line). The tables 
contain information on the effect (% of mortality) elicited by each test concentration, in the presence or absence of the 
respective inhibitor, as assessed by the lactate dehydrogenase (LDH) leakage assay and 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) reduction assay. 
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Table 14 Amount of 3-methylmethcahinone (3-MMC) metabolized.  
Concentration 
(mM) 
Control 
CYP2D6 
Inhibition 
CYP3A4 
Inhibition 
CYP2E1 
Inhibition 
CYP450 
Inhibition 
Met Viab Met Viab Met Viab Met Viab Met Viab 
0.8 78.9 81.8 86.0 - 100.5 96.7 89.9 95.4 82.5 91.6 
1 77.5 94.7 81.8 - 84.6 94.4 84.1 71.9 93.7 91.4 
1.6 94.1 76.4 94.6 - 89.4 36.3 78.3 8.0 95.5 37.3 
All values are in percentage (%). The percentage of metabolization was calculated as follows: % metabolism = 
(concentration of 3-MMC to which cells were exposed to / concentration of 3-MMC detected by GC-MS) x 100. Met – 
metabolization; Viab – viability.  
In the absence of metabolic inhibition (controls), an increase in the extent of 
metabolism was observed with increasing concentrations of 3-MMC (78.9 % at 0.8 mM 
and 94.1 % at 1.6 mM), denoting no apparent saturation of normal 3-MMC metabolic 
pathways. 
When CYP2E1 was inhibited, at the low concentration range (up to approximately 
1.20 mM), the toxicity diminished (Fig. 18) and the metabolism of 3-MMC seemed to 
increase (Fig. 19). Taken together, these observations appear to indicate that the drug 
followed more efficient alternative metabolic pathways (higher metabolic rate) and that 
the degradation of 3-MMC diminished the toxicity (metabolism through these 
alternative pathways contributed to the drug detoxification). Nevertheless, at higher 
concentrations, an inversion of the cytotoxic profile was noted. Accordingly, an 
enhancement of the toxicity occurred. Also, at this concentration level an apparent 
reduction of metabolism was observed, compared to that at lower concentrations (Figs. 
18 and 19). This might be due to the saturation of the alternative metabolic pathways 
(for instance, through other CYP450 isoforms). 
When inhibiting CYP2D6, the toxicity decreased but only a slight increase in the 
extent of 3-MMC metabolism occurred, compared to controls, particularly at the lower 
concentrations tested (Table 14 and Fig. 19). Metabolism though this isoform seems to 
be toxifying, as previously observed for the amphetamine-derivative MDMA, in 
cardiomyocytes (Carvalho et al. 2004). Accordingly, the opening of the methylenedioxy 
ring of MDMA and its metabolite 3,4-methylenedioxyamphetamine (MDA) occurs 
through CYP2D6 and originates two catechol metabolites, N-methyl-α-methyldopamine 
(N-Me-α-MeDA) and α-methyldopamine (α-MeDA), respectively. The presence of the 
catechol group confers high reactivity to these metabolites, which easily oxidize, giving 
the corresponding o-quinones. The oxidation of quinones may also cause the formation 
of aminochromes, whose subsequent oxidation leads to the production of polymers of 
melanin type. The cycles of reduction-oxidation (redox) associated with this metabolic 
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conversion result in the formation of ROS/RNS, which similarly to what occurs with 
quinones, might attack relevant intracellular nucleophilic groups, such as protein 
sulfhydryl groups e.g. GSH), resulting in significant modification of macromolecules, 
including proteins, lipids and deoxyribonucleic acid (DNA) (Carvalho et al. 2012). 
On the contrary, when CYP3A4 was inhibited, the increase of 3-MMC 
concentration apparently reduced the drug metabolism, compared to controls. 
However, this alteration did not seem to have a significant impact, as no effect on the 
cytotoxic profile of 3-MMC was noted upon CYP3A4 inhibition (Fig. 18; Table 14). 
Finally, when inhibiting the whole CYP450, the metabolism apparently increased, 
in comparison with the control, mostly at the low concentrations tested (Table 14). 
However, at these concentrations, no difference in toxicity was noted, when compared 
with the control (Fig. 19). Surprisingly, the difference in toxicity was only noted at the 
higher concentration range (from 1.03 mM on; Fig. 18), for which metabolism through 
CYP450 seemed to be detoxifying. If the whole CYP450 is inhibited, the metabolism 
might be occurring though other enzymes. For instance, through catechol-O-
methyltransferase (COMT), as described for the hepatic metabolism of MDMA (Dias da 
Silva et al. 2013b). One could therefore speculate that the metabolism of 3-MMC is 
also regulated through the latter enzyme. 
Fig. 19 Percentage of 3-methylmethcathinone (3-MMC) metabolized when CYP2D6 (yellow), CYP3A4 (red), 
CYP2E1 (blue) and CYP450 (green) are inhibited and when no inhibition is made (black). 
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Chapter 5 
Conclusion and future perspectives 
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With the increase in consumption and the lack of toxicological studies on 3-MMC, 
its toxicity assessment has become mandatory. For the first time, the in vitro 
hepatotoxic effects of 3-MMC have been demonstrated. This synthetic cathinone 
induced oxidative stress, loss of mitochondrial membrane potential, GSH and ATP 
depletion, increased GSSG, as well as caspase-3, -8, and -9 activation. Drug 
metabolism through CYP2D6 might be involved in the toxicological effects of 3-MMC, 
while CYP2E1 might be responsible for detoxification, particularly at high 
concentrations (above 1.20 mM). Bioactivation of 3-MMC by CYP2D6 and, for the low 
concentration range, by CYP2E1 is involved in the observed toxicity. The results of the 
GC-MS also showed comparable results. 
Overall, data presented herein allowed us to conclude that: 
i) Hepatotoxicity of 3-MMC might be triggered both by mitochondria-
dependent (intrinsic) and mitochondria-independent (extrinsic) pathways of apoptotic 
cell death; 
ii) At higher drug concentrations, other cell death pathways might be at 
play, such as necrosis; 
iii) Oxidative stress and alterations on energy homeostasis might be 
mediating the observed effects; 
iv) Bioactivation of 3-MMC by CYP2D6 and CYP2E1 (at concentrations 
lower than 1.20 mM) might be involved in the observed toxicity; 
v) The metabolism might also occur through other enzymes besides 
CYP450. 
The present study is a starting point in the research concerning 3-MMC and, 
therefore, further investigation is required to elucidate users that should be alert of the 
risks associated with the abuse of this substance. Future perspectives may potentially 
involve the following work: 
i) To clarify the other pathways of cell death (necrosis and autophagy); 
ii) To evaluate other stress markers, such as quantification of intercellular 
calcium; 
iii) To explore the role of hyperthermia in the toxicity of this drug; 
iv) To validate the significance of in vitro data presented in this thesis 
through in vivo studies; 
v) To further develop and validate a method for GC-MS identification and 
quantification of both 3-MMC and its metabolites. 
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Introduction: In the recent years, there has been an increase in the production of new 
psychoactive substances (NPS). As some NPS are still considered legal in some countries, users 
mistakenly consider them as safe for consumption. However, several cases of intoxications and 
deaths related to NPS have been recently reported (1). An example of such a drug is 3-
methylmethcathinone (3-MMC or metaphedrone). This drug belongs to the synthetic 
cathinones family and was recently introduced in the market to replace 4-methylmethcathinone 
(4-MMC or mephedrone), which became illegal. There is some evidence of 3-MMC being as 
dangerous as 4-MMC (2) but information on 3-MMC toxic profile is profoundly scarce. 
Aims: As the liver is one of the main sites of drug metabolism, and therefore a relevant target 
for their deleterious effects, the aim of this project was to assess the hepatotoxicity of 3-MMC. 
Material and methods: For this purpose, primary hepatocytes of Wistar rats were isolated by 
collagenase perfusion, cultured, and exposed for 24 h to several concentrations of the drug, 
selected to provide a complete cytotoxic profile. Cell death was assessed through three assays, 
namely the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction 
assay, lactate dehydrogenase (LDH) leakage assay, and the neutral red (NR) uptake assay. 
Afterwards, some of the mechanisms that contributed to the putative cytotoxicity were also 
assessed by measuring the intracellular reactive species of oxygen and nitrogen (ROS/RNS), 
alterations to the mitochondrial membrane potential (ΔΨm), and to caspase activities, after 
exposing cells at 1 μM, 10 μM, 100 μM, and 500 µM of 3-MMC. Finally, we evaluated the 
modulatory effects of cytochrome P450 (CYP) inhibitors on the toxicity of 3-MMC. 
Results: 3-MMC-induced toxicity was firstly perceived in the lysosome (NR NOEC 312.5 
µM), next in the mitochondria (MTT NOEC 379.5 µM), and finally in the cytoplasmic 
membrane (LDH NOEC 1.04 mM). A significant concentration-dependent increase of 
ROS/RNS was observed from 10 μM on. At this concentration, caspase -3, -8, and -9 activities 
were significantly elevated, but no differences were observed at higher concentrations, 
indicating that at these levels other mechanisms should intervene. No significant alterations 
were observed in the ΔΨm, which is important for ATP synthesis, and therefore for energy-
dependent apoptosis. CYP 2D6, 2E1, and 3A4 inhibitors diminished 3-MMC toxicity. 
Conclusions: Overall, our data point to a role of metabolism in the hepatotoxicity of 3-MMC, 
which seems to be triggered both by intrinsic and extrinsic apoptotic mechanisms. At higher 
drug concentrations, other cell death pathways might be at play, such as necrosis or autophagy, 
deserving further investigation. 
 
1 - EMCDDA European Drug Report 2016; 2 - Adamowicz P et al. Journal of Analytical 
Toxicology 2016; 40(4):272-6.  
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3-Methylmethcathinone (3-MMC or metaphedrone) is a new psychoactive synthetic cathinone 
that has been recently deemed responsible for several cases of intoxications and deaths, as a 
consequence of its use in recreational settings. As the liver is one of the main sites of 
metabolism of drugs, the aim of this study was to assess the hepatotoxicity of 3-MMC. 
For this purpose, primary hepatocytes of Wistar rats were isolated by collagenase perfusion, 
cultured and exposed for 24 h to several concentrations of the drug, selected to provide a 
complete cytotoxic profile. Cell death was assessed through three assays, namely the MTT 
reduction assay, LDH leakage assay, and the neutral red (NR) uptake assay. Afterwards, some 
of the mechanisms that contributed to the putative cytotoxicity were also assessed by 
measuring the intracellular ROS and RNS, the alterations to mitochondrial membrane 
potential, and to caspase -3, -8, and -9 activities, after exposing cells at 1 μM, 10 μM, 100 
μM, and 500 µM of 3-MMC. 
3-MMC-induced toxicity was firstly perceived in the lysosome (NR NOEC 312.5 µM), next 
in the mitochondria (MTT NOEC 379.5 µM), and finally in the cytoplasmic membrane (LDH 
NOEC 1.04 mM). An increase of ROS and RNS was observed in a concentration-dependent 
manner, statistically significant from 10 μM on. At this concentration, caspase -3, -8, and -9 
activities were significantly elevated, but no differences were observed at higher doses, 
indicating that at these levels other mechanisms should intervene. No significant alterations 
were observed in the mitochondrial membrane potential, which is important for ATP 
synthesis, and therefore for energy-dependent apoptosis. 
Overall, our data indicate that hepatotoxicity of 3-MMC is triggered both by intrinsic and 
extrinsic apoptotic mechanisms but, at higher drug concentrations, other cell death pathways 
might be at play, such as necrosis or autophagy, deserving further investigation. 
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Introduction: The XXI century has been witnessing a change in paradigm of drug abuse, through a steadily 
increase in the production of new psychoactive substances (NPS). As they are still legal in some countries, users 
mistakenly consider them safe. However, there are several reports of intoxications and deaths by NPS [1]. The 
synthetic cathinone 3-methylmethcathinone (3-MMC or metaphedrone) was recently introduced in the market to 
replace the illegal drug 4-methylmethcathinone (4-MMC or mephedrone). There is evidence of 3-MMC being as 
dangerous as 4-MMC to humans [2] but information on the toxicity mechanisms is scarce, demanding 
investigation. 
Aims: As the liver is one of the main sites of cathinones’ metabolism, and therefore a relevant target for their 
deleterious effects, the aim of this project was to assess the mechanistic pathways of toxicity of 3-MMC in primary 
rat hepatocytes. 
Material and methods: Primary hepatocytes of Wistar rats were isolated by collagenase perfusion, cultured, and 
exposed for 24 h to the drug at a concentration range [from 31 nM to 10 mM] selected to provide a complete 
cytotoxic profile. Cell death was assessed through three assays, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) reduction assay, lactate dehydrogenase (LDH) leakage assay, and the neutral 
red (NR) uptake assay. Some of the mechanisms that could contribute to the observed cytotoxicity were also 
assessed by measuring the intracellular reactive species of oxygen and nitrogen (ROS/RNS), reduced (GSH) and 
oxidized (GSSG) glutathione, adenosine triphosphate (ATP), alterations to the mitochondrial membrane potential 
(ΔΨm) and to caspase activities, after exposing cells to 1 μM, 10 μM, 100 μM, and 500 µM of 3-MMC. Finally, the 
modulatory effects of cytochrome P450 (CYP) inhibitors on the toxicity of 3-MMC were also evaluated. 
Results: 3-MMC-induced toxicity was perceived in the lysosome at lower concentrations (NR NOEC 312.5 µM), 
compared to mitochondria (MTT NOEC 379.5 µM) and to cytoplasmic membrane (LDH NOEC 1.04 mM). A 
significant concentration-dependent increase of ROS/RNS was observed from 10 μM on. At this concentration, 
caspase -3, -8, and -9 activities were significantly increased, but no differences were observed at higher 
concentrations, indicating that at this level other cell death mechanisms may intervene. No significant alterations 
were observed in the ΔΨm, which is important for ATP synthesis, and therefore for energy-dependent apoptosis. 
ATP intracellular content slightly increased at 1 μM and significantly decreased at the highest concentrations (100 
μM and 500 μM). We observed a concentration-dependent decrease in antioxidant defences (GSH) with a 
concurrent increase of GSSG. CYP2D6 and 2E1 inhibition diminished 3-MMC toxicity, but for CYP2E1 this effect 
was only observed for concentrations up to 1.3 mM. 
Conclusions: Overall, our data point to a role of metabolism in the hepatotoxicity of 3-MMC, which seems to be 
triggered both by intrinsic and extrinsic apoptotic mechanisms. At higher drug concentrations, other cell death 
pathways might be at play, such as necrosis or autophagy, deserving further investigation. 
 
References: 
1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2016: Trends 
and Developments. European Monitoring Centre for Drugs and Drug Addiction, Lisbon. 2016 
2. Adamowicz P, Gieron J, Gil D, Lechowicz W, Skulska A, Tokarczyk B. 3-Methylmethcathinone-Interpretation 
of Blood Concentrations Based on Analysis of 95 Cases. Journal of Analytical Toxicology 40:272-276, 2016 
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Results
Figure 3 – Effect of 3-MMC on ROS and RNS production (left) and on the mitochondrial 
membrane potential, as measured by (TMRE) incorporated within the mitochondria (right)
Figure 4 – Caspase -3, -8 and -9 activation after exposure to 3-MMC for 24h
Figure 5 – Effect of 3-MMC on ATP intracellular content
Figure 6 – Effect of 3-MMC on the total (tGSH) and reduced glutathione (redGSH), and on 
GSH/GSSG ratio
CYTOTOXICITY OF 3-METHYLMETHCATHINONE (3-MMC OR METAPHEDRONE) IN
PRIMARY RAT HEPATOCYTES
Bárbara Ferreira1,2, Diana Dias da Silva2, Rita Rebelo2, Patrícia Moreira2, Félix Carvalho2, Maria de Lourdes Bastos2, 
Helena Carmo2
1Department of Legal Medicine and Forensic Sciences, Faculty of Medicine, University of Porto, Portugal
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Introduction
The XXI century has been witnessing a change in paradigm of drug abuse,
through a steadily increase in the production of new psychoactive
substances (NPS). As they are still legal in some countries, users mistakenly
consider them safe. However, there are several reports of intoxications and
deaths by NPS [1]. The synthetic cathinone 3-methylmethcathinone (3-MMC
or metaphedrone) was recently introduced in the market to replace the
illegal drug 4-methylmethcathinone (4-MMC or mephedrone). However,
there is evidence of 3-MMC being as dangerous as 4-MMC to humans [2]
though information on the toxicity mechanisms is scarce, demanding further
investigation.
Aim
As the liver is one of the main sites of cathinones’ metabolism, and
therefore a relevant target for their deleterious effects, the aim of this study
was to assess the pathways of toxicity of 3-MMC in primary rat hepatocytes.
Material and methods
Primary hepatocytes of Wistar rats were isolated by collagenase perfusion,
cultured, and exposed for 24 h to the drug at a concentration range [from 31
nM to 10 mM] selected to provide a complete cytotoxic profile. Cell death
was assessed through three assays, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) reduction assay, lactate dehydrogenase
(LDH) leakage assay, and the neutral red (NR) uptake assay. Some of the
mechanisms that could contribute to the observed cytotoxicity were also
assessed by measuring the intracellular reactive oxygen and nitrogen species
(ROS/RNS), reduced (GSH) and oxidized (GSSG) glutathione, adenosine
triphosphate (ATP), alterations to the mitochondrial membrane potential
(ΔΨm) and to caspase activities, after exposing cells to 1 μM, 10 μM, 100
μM, and 500 µM of 3-MMC. The modulatory effects of cytochrome P450
(CYP) inhibitors on the toxicity of 3-MMC were also evaluated.
Conclusions
Overall, metabolism seems to be implicated in the hepatotoxicity of 3-MMC,
which is suggested to be triggered both by intrinsic and extrinsic apoptotic
pathways. At higher drug concentrations, other cell death mechanisms
might be at play, such as necrosis or autophagy, deserving further
investigation.
References
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Results
Figure 1 – Concentration–response curves obtained with the MTT reduction assay, LDH leakage 
assay and NR uptake assay.
Table 1 – NOEC and EC50 of MTT reduction assay, LDH leakage assay and  NR uptake assay
Figure 2 – Effect of the CYP 3A4, 2D6, 2E1 and general CYP450 inhibitors on the metabolism of 
3-MMC
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